WO1997024120A1 - THIENO(2,3-b)PYRAZOLO(3,4-d)PYRIDIN-3-ONES TO ENHANCE ERYTHROPOIESIS - Google Patents

THIENO(2,3-b)PYRAZOLO(3,4-d)PYRIDIN-3-ONES TO ENHANCE ERYTHROPOIESIS Download PDF

Info

Publication number
WO1997024120A1
WO1997024120A1 PCT/US1996/020418 US9620418W WO9724120A1 WO 1997024120 A1 WO1997024120 A1 WO 1997024120A1 US 9620418 W US9620418 W US 9620418W WO 9724120 A1 WO9724120 A1 WO 9724120A1
Authority
WO
WIPO (PCT)
Prior art keywords
branched
linear
pyridin
pyrazolo
hexahydro
Prior art date
Application number
PCT/US1996/020418
Other languages
French (fr)
Inventor
Juan Ignacio Luengo
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Priority to BR9612302A priority Critical patent/BR9612302A/en
Priority to JP09524480A priority patent/JP2000507206A/en
Priority to EP96945632A priority patent/EP0869790A4/en
Priority to AU16867/97A priority patent/AU1686797A/en
Priority to IL12503596A priority patent/IL125035A0/en
Priority to KR1019980704948A priority patent/KR19990076822A/en
Publication of WO1997024120A1 publication Critical patent/WO1997024120A1/en
Priority to NO983007A priority patent/NO983007L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Definitions

  • anemia of chronic renal failure results in reduced erythrocyte production due to diminished kidney erythropoietin (EPO) secretion.
  • EPO is produced by the kidneys in response to renal delivery of oxygen and its principal site of action is the erythroid lineage in the bone marrow. It regulates the proliferation and differentiation of erythroid precursor cells allowing for adequate erythrocyte production.
  • Clinical trials of replacement therapy in patients with end-stage renal disease have established that erythropoietin can correct anemia in these patients by enhancing erythropoiesis.
  • the ability to enhance erythropoiesis resulting from or independent of chronic renal failure is considered an attractive therapy for anemias, cytopenias, and other conditions with depressed erythrocyte production.
  • the present invention resides in the discovery that certain substituted thieno[2,3-b]pyrazolo[3,4-d]pyridin-3-ones enhance erythropoiesis in mammals, including humans.
  • compositions comprising a pharmaceutical carrier and compounds useful in the methods of the invention.
  • enhancing erythropoiesis means increacing the production of erythrocytes.
  • treating means prophylactic or therapeutic therapy.
  • the presently invented compounds of this invention that enhance erythropoiesis have the following Formula (I):
  • X is O or NR 5 , where R 5 is hydrogen, or selected from: linear or branched C ⁇ galkyl, -(CH2) n C3-7cycloalkyl, linear or branched C2-6alkenyl, linear and branched C2-6alkynyl or -(CH2) n Ar, all of which are optionally substituted with one or more substituents selected from the group consisting of: -OH, -OR 6 , -CONR 6 R 7 , -NR 6 R 7 , -COR 6 , - CO2R 6 , -SO2NHR 6 , -NHCOR 6 and halogen, where n is 0 to 6, and R 6 and R 7 are:
  • R 6 and R 7 when attached to the same nitrogen atom R 6 and R 7 can join together to form a ring selected from the group consisting of: piperidyl, morpholynyl, piperazinyl and pyrrolidyl;
  • R 1 is hydrogen, or selected from: linear or branched Ci ⁇ alkyl, -(CH2) n C3_7cycloalkyl, linear or branched C2-6alkenyl, linear or branched C2_6 a lkynyl and -(CH2) n r, all of which are optionally substituted with one or more substituents selected from the group consisting of: -OH, -OR 6 , -CONR 6 R 7 , -NR R 7 , -COR 6 , -CO R 6 , -SO2NHR 6 , - NHCOR 6 and halogen, where n, R 6 and R 7 have the same meaning as above; and R 2 and R 3 are
  • X is O or NR 5 , where R 5 is hydrogen, or selected from: linear or branched Cj.galkyl, -(CH2) n C3-7cycloalkyl, linear or branched C2_6al enyl, linear and branched C2-6 l ynyl or -(CH2) n r, where n is 0 to 6; Rl is hydrogen, or selected from: linear or branched C ⁇ alkyl, -(CH2) n C3_7cycloalkyl, linear or branched C2-6al enyl, linear or branched C2-6alkynyl and -(CH2)nAr, where n has the same meaning as above; and
  • X is NR 5 , where R 5 is hydrogen, or selected from: linear or branched Cj ⁇ alkyl, C3_7cycloalkyl and phenyl;
  • Rl is hydrogen, or selected from: linear or branched Cj.galkyl, C3_7cycloalkyl and phenyl;
  • R 2 and R 3 are (i) hydrogen, or independently selected from: linear or branched Cj.galkyl, C3_7cycloalkyl and phenyl,
  • R 2 and R 3 are joined together to form a non aromatic saturated or unsaturated C5_7cycloalkyl, optionally containing one nitrogen heteroatom, and optionally substituted with one or more substituents selected from the group consisting of: ethylenedioxy, linear or branched Ci _6alkyl, C3_7cycloalkyl, phenyl,-
  • R 2 and R 3 are joined together to form a phenyl ring, optionally substituted with one or more substituents selected from the group consisting of: halogen, -OH, linear or branched Ci.galkyl, C3_7cycloalkyl and phenyl; except 2,3,7,8,9, 10-Hexahydro-4-methyl- 1 H-[ 1 ]benzothieno[2,3-b]pyrazolo[3,4- d]pyridin-3-one and 8,8-Ethylenedioxy-2,3,7,8,9, 10-hexahydro-4-methyl-lH- [l]benzothieno[2,3-b]pyrazolo[3,4-d]pyridin-3-one.
  • substituents selected from the group consisting of: halogen, -OH, linear or branched Ci.galkyl, C3_7cycloalkyl and phenyl; except 2,3,7,8,9, 10-Hexahydro-4-methyl- 1
  • Preferred among the presently invented compounds are: 2,3-Dihydro-4-methyl-lH-[l]benzothieno[2,3-b]pyrazolo[3,4-d]pyridin-3- one and pharmaceutically acceptable salts, hydrates and solvates thereof;
  • X is O or NR 5 , where R 5 is hydrogen, or selected from: linear or branched Cj.galkyl, -(CH2) n C3_7cycloalkyl, linear or branched C2_6alkenyl, linear and branched C2-6alkynyl or -(CH2) n Ar, all of which are optionally substituted with one or more substituents selected from the group consisting of: -OH, -OR 6 , -CONR 6 R 7 , -NR 6 R 7 , -COR 6 , - CO 2 R 6 , -SO 2 NHR 6 , -NHCOR 6 and halogen, where n is 0 to 6, and R 6 and R 7 are: (i) hydrogen, or independently selected from: H, linear or branched C ⁇ galkyl, C3.
  • R 6 and R 7 when attached to the same nitrogen atom R 6 and R 7 can join together to form a ring selected from the group consisting of: piperidyl, morpholynyl, piperazinyl and pyrrolidyl;
  • Rl is hydrogen, or selected from: linear or branched Cj.galkyl, -(CH2) n C3-7cycloalkyl, linear or branched C2-6alkenyl, linear or branched C2_6alkynyl and -(CH2) n Ar, all of which are optionally substituted with one or more substituents selected from the group consisting of: -OH, -OR 6 , -CONR 6 R 7 , -NR R 7 , -COR 6 , -CO2R 6 , -SO NHR 6 , - NHCOR 6 and halogen, where n, R 6 and R 7 have the same meaning as above; and R 2 and R 3 are (i) hydrogen, or independently selected from:
  • ⁇ cycloalkyl optionally containing one or two heteroatoms, and optionally substituted with one or more substituents selected from the group consisting of: ethylenedioxy, linear or branched C ⁇ alkyl, - (CH2) n C3-7cycloalkyl, linear or branched C2-6alkenyl, linear or branched
  • X is O or NR 5 , where R 5 is hydrogen, or selected from: linear or branched C ⁇ galkyl, -(CH2) n C3_7cycloalkyl, linear or branched C2-6alkenyl, linear and branched C2_6 lkynyl or -(CH2) n Ar, where n is 0 to 6; Rl is hydrogen, or selected from: linear or branched Cj.galkyl, -(CH2) n C3-7cycloalkyl, linear or branched C2_6alkenyl, linear or branched C2-6alkynyl and -(CH2) n Ar, where n has the same meaning as above; and
  • Rl is hydrogen, or selected from: linear or branched Cj ⁇ alkyl, C3_7cycloalkyl and phenyl;
  • R 2 and R 3 are joined together to form a phenyl ring, optionally substituted with one or more substituents selected from the group consisting of: halogen, -OH, linear or branched C ⁇ _6alkyl, C3_7cycloalkyl and phenyl; except 2,3,7,8,9,10-Hexahydro-4-methyl-lH-[l]benzothieno[2,3-b]pyrazolo[3,4- d]pyridin-3-one and 8,8-Ethylenedioxy-2,3,7,8,9,10-hexahydro-4-methyl-lH-
  • Preferred compounds of the present invention that enhance erythropoiesis are:
  • AR phenyl, naphthyl, furyl, pyrrolyl, thienyl, isothiazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrazinyl, pyrimidyl, pyridazinyl, carbazolyl, indolyl, quinolyl or purinyl.
  • C x .yCycloalkyl as used herein is meant a nonaromatic, unsaturated or saturated, cyclic or poly cyclic compound having from x to y carbons.
  • C x .yCycloalkyl can include one or two heteroatoms.
  • Examples of C x _ycycloalkyl as used herein include: cylcohexyl and cyclopentyl.
  • heteroatom as used herein is meant O or N.
  • halogen as used herein is meant F, Cl, Br or I.
  • Formula (I) compounds are prepared as shown in Scheme I below provided that the 'R' substituents do not include any such substituents that render inoperative the Scheme I process.
  • R is as described above; in a suitable solvent , such as toluene, at reflux in the presence of an acid catalyst, such as camphorsulfonic acid, and with azeotropic removal of water using a Dean- Stark trap.
  • a suitable solvent such as toluene
  • an acid catalyst such as camphorsulfonic acid
  • azeotropic removal of water using a Dean- Stark trap The resulting material is treated with 1 M sodium ethoxide solution and reflux to provide a thieno[2,3-b]pyridine of Formula (6)
  • R 2 and R 3 are joined together to form a non aromatic saturated or unsaturated C3.
  • ⁇ cycloalkyl optionally containing one or two heteroatoms, and optionally substituted with one or more substituents selected from the group consisting of: ethylenedioxy, linear or branched C ⁇ galkyl, -(CH2) n C3_7cycloalkyl, linear or branched C2-6 a lkenyl, linear or branched C2-6 a lkynyl, -(CH2) n Ar, -OH, -OR 6 , - CONR 6 R 7 , -COR 6 , -CO 2 R 6 , -SO 2 NHR 6 , -NHCOR 6 and halogen, where n, R 6 and R 7 have the same meaning as in Formula (I).
  • R 5 is as described in Formula (I) above; in a solvent, such as methanol, at reflux and thereafter optionally forming a pharmaceutically acceptable salt, hydrate or solvate thereof.
  • R J 2 where R 5 is as described in Formula (I) above; in a solvent, such as methanol, at reflux and thereafter optionally forming a pharmaceutically acceptable salt, hydrate or solvate thereof.
  • a solvent such as methanol
  • HO ⁇ H in a solvent, such as methanol, at reflux and in the presence of a base, such as triethylamine or sodium hydroxide, and thereafter optionally forming a pharmaceutically acceptable salt, hydrate or solvate thereof.
  • a solvent such as methanol
  • a base such as triethylamine or sodium hydroxide
  • R 2 and R 3 are as described in Formula (I) above, including the exceptions, and pharmaceutically acceptable salts, hydrates and solvates thereof comprises reacting a compound of the Formula
  • a solvent such as methanol
  • a base such as triethylamine or sodium hydroxide
  • UT7/EPO cells express human EPO receptors on their cell surface and respond to EPO by cell proliferation. Proliferation of UT7/EPO cells in response to EPO or to compounds of the present invention was quantitated using a MTT assay as described in T. Mosmann (1983) J. Immunol. Methods Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays 65:55-63.
  • UT7/EPO cells were grown in growth medium ( Iscove's Modified Dulbecco's Medium with L-glutamine and 25 mM HEPES buffer) (IMDM medium) with 0.4U/ml recombinant human EPO (Amgen) and 10% fetal bovine serum (FBS) to a cell density of approximately 5 x 10 5 cells/ml.
  • IMDM medium Iscove's Modified Dulbecco's Medium with L-glutamine and 25 mM HEPES buffer
  • FBS fetal bovine serum
  • a compound of the present invention (or EPO) was added to the wells by serial dilution, maintaining a final volume of 0.1 ml.
  • the treated cells were incubated in a humidified incubator at 37°C and 5% CO 2 for 2 - 3 days.
  • 0.04 mg MTT [(3-[4,5-Dimthylthiazol-2-y]-2,5- diphenyltetrazolium bromide] was added to every well in a volume of 0.025 ml and incubated for 4 hours.
  • the MTT reaction was stopped by addition of 10% SDS in 0.0 IN HCL and solubilized overnight at 37°C.
  • Proliferation was quantitated colorimetrically at 570/750 nM using a BioTek II Microplate Reader. The increase in OD 570/750 is proportional to cell growth.
  • the pharmaceutically active compounds within the scope of this invention are useful in enhancing erythropoiesis in mammals, including humans, in need thereof.
  • the pharmaceutically active compounds of the present invention are inco ⁇ orated into convenient dosage forms such as capsules, tablets, or injectable preparations.
  • Solid or liquid pharmaceutical carriers are employed.
  • Solid carriers include, starch, lactose, calcium sulfate dihydrate, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate and stearic acid.
  • Liquid carriers include syrup, peanut oil, olive oil, saline, and water.
  • the carrier or diluent may include any prolonged release material, such as glyceryl monostearate or glyceryl distearate, alone or with a wax.
  • the amount of solid carrier varies widely but, preferably, will be from about 25 mg to about lg per dosage unit.
  • the preparation will be in the form of a syrup, elixir, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampoule, or an aqueous or nonaqueous liquid suspension.
  • the pharmaceutical preparations are made following conventional techniques of a pharmaceutical chemist involving mixing, granulating, and compressing, when necessary, for tablet forms, or mixing, filling and dissolving the ingredients, as appropriate, to give the desired oral or parenteral products.
  • Doses of the presently invented pharmaceutically active compounds in a pharmaceutical dosage unit as described above will be an efficacious, nontoxic quantity preferably selected from the range of 0.001 mg per kg and 100.0 mg per kg of subject body weight, preferably 0.001 - 10 mg kg.
  • the active compounds may be administered to a patient in need of enhanced erythropoiesis by any conventional route of administration, including, but not limited to, intravenous, intramuscular, oral, subcutaneous, intradermal, and parenteral.
  • the selected dose is administered preferably from 1-6 times daily, orally or parenterally.
  • Preferred forms of parenteral administration include topically, rectally, transdermal ly, by injection and continuously by infusion.
  • Oral dosage units for human administration preferably contain from 0.05 to 500 mg of active compound.
  • Oral administration, which uses lower dosages is preferred.
  • Parenteral administration, at high dosages, however, also can be used when safe and convenient for the patient.
  • Optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the particular pharmaceutically active compound in use, the strength of the preparation, the mode of administration, and the advancement of the disease condition. Additional factors depending on the particular patient being treated will result in a need to adjust dosages, including patient age, weight, diet, and time of administration.
  • the method of this invention of enhancing erythropoiesis in mammals, including humans comprises administering to a subject in need of such therapy an effective erythropoiesis enhancing amount of a pharmaceutically active compound of the present invention.
  • the invention also provides for the use of a compound of Formula (III) in the manufacture of a medicament for use in enhancing erythropoiesis.
  • the invention also provides for a pharmaceutical composition for use in the treatment of anemias which comprises a compound of Formula HI and a pharmaceutically acceptable carrier.
  • the invention also provides for a pharmaceutical composition for use in the treatment of cytopenias which comprises a compound of Formula III and a pharmaceutically acceptable carrier.
  • the invention also provides for a process for preparing a pharmaceutical composition containing a pharmaceutically acceptable carrier or diluent and a compound of Formula III which comprises bringing the compound of Formula III into association with the pharmaceutically acceptable carrier or diluent. No unacceptable toxicological effects are expected when compounds of the invention are administered in accordance with the present invention.
  • the pharmaceutically active compounds of the present invention can be co-administered with further active ingredients, such as other compounds known to enhance erythropoiesis. Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent.
  • N- r/-Butoxycarbonyl-4-( 1 -cyano- 1 -ethoxycarbonyl)methylenepiperidine To a mixture of N-tert-butoxycarbonyl-4-piperidone (25 g, 0.125 mol) and ethyl cyanoacetate (18 g, 0.160 mol) in toluene (400 mL) was added dropwise diethylamine (18.25 g, 0.25 mol) at room temperature. The reaction mixture was heated at reflux overnight, using a Dean Stark apparatus. The mixture was cooled and partitioned with ethyl acetate and saturated aqueous sodium bicarbonate (3x).
  • EXAMPLE 7 An oral dosage form for administering Formula (HI) comounds is produced by screening, mixing, and filling into hard gelatin capsules the ingredients in the proportions shown in Table 1, below.
  • EXAMPLE 8 The sucrose, calcium sulfate dihydrate and Formula (III) compound shown in Table II below, are mixed and granulated in the proportions shown with a 10% gelatin solution. The wet granules are screened, dried, mixed with the starch, talc and stearic acid, screened and compressed into a tablet.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Invented are substituted thieno(2,3-b)pyrazolo(3,4-d)pyridin-3-ones, pharmaceutical compositions containing these compounds, and methods of using these compounds to enhance erythropoiesis. Also invented are intermediates and processes used in preparing these compounds.

Description

THIENOr2.3-blPYRAZOLOr3.4-dlPYRIDIN-3-ONES TO ENHANCE ERYTHROPOIESIS
BACKGROUND OF THE INVENTION Typically, anemia of chronic renal failure results in reduced erythrocyte production due to diminished kidney erythropoietin (EPO) secretion. EPO is produced by the kidneys in response to renal delivery of oxygen and its principal site of action is the erythroid lineage in the bone marrow. It regulates the proliferation and differentiation of erythroid precursor cells allowing for adequate erythrocyte production. Clinical trials of replacement therapy in patients with end-stage renal disease have established that erythropoietin can correct anemia in these patients by enhancing erythropoiesis.
The ability to enhance erythropoiesis resulting from or independent of chronic renal failure is considered an attractive therapy for anemias, cytopenias, and other conditions with depressed erythrocyte production.
It would be desirable to provide compounds which allow for the enhancement of erythropoiesis.
As disclosed herein it has unexpectedly been discovered that certain selected thieno[2,3-b]pyrazolo[3,4-d]pyridin-3-ones are effective in enhancing erythropoiesis in mammals, including humans.
SUMMARY OF THE INVENTION The present invention resides in the discovery that certain substituted thieno[2,3-b]pyrazolo[3,4-d]pyridin-3-ones enhance erythropoiesis in mammals, including humans.
Presently preferred compounds of the invention which are used in the invented pharmaceutical compositions and the invented methods include:
2,3,7,8,9,10-Hexahydro-4-methyl-lH-[l]benzothieno[2,3-b]pyrazolo[3,4- d]pyridin-3-one; 2,3-Dihydro-4-methyl-lH-[l]benzothieno[2,3-b]pyrazolo[3,4-d]pyridin-3- one; 8,8-Ethylenedioxy-2,3,7,8,9,10-hexahydro-4-methyl-lH-[l]benzothieno[2,3- b]pyrazolo[3,4-d]pyridin-3-one;
1 ,4-Dimethyl-8,8-ethylenedioxy-2,3,7,8,9, 10-hexahydro- 1 H- [l]benzothieno[2,3-b]pyrazolo[3,4-d]pyridin-3-one; 8-tert-Butoxycarbonyl-2,3,7,8,9, 10-hexahydro-4-methyl- 1H- pyrido[4',3':4,5]thieno[2,3-b]pyrazolo[3,4-d]pyridin-3-one; and
2,3,7,8,9,10-Hexahydro-4-methyl-lH-pyrido[4',3':4,5]thieno[2,3- b]pyrazolo[3,4-d]pyridin-3-one.
In a further aspect of the invention there are provided novel intermediates and novel processes useful in preparing the presently invented compounds.
Included in the present invention are pharmaceutical compositions comprising a pharmaceutical carrier and compounds useful in the methods of the invention.
DETAILED DESCRIPTION OF THE INVENTION
As used herein, the term "enhancing erythropoiesis" means increacing the production of erythrocytes.
As used herein, the term "treating" and derivatives thereof means prophylactic or therapeutic therapy. The presently invented compounds of this invention that enhance erythropoiesis have the following Formula (I):
Figure imgf000004_0001
wherein:
X is O or NR5, where R5 is hydrogen, or selected from: linear or branched C^galkyl, -(CH2)nC3-7cycloalkyl, linear or branched C2-6alkenyl, linear and branched C2-6alkynyl or -(CH2)nAr, all of which are optionally substituted with one or more substituents selected from the group consisting of: -OH, -OR6, -CONR6R7, -NR6R7, -COR6, - CO2R6, -SO2NHR6, -NHCOR6 and halogen, where n is 0 to 6, and R6 and R7 are:
(i) hydrogen, or independently selected from: H, linear or branched Cj^alkyl, C3. cycloalkyl, linear or branched C2-6alkenyl, linear or branched C2- galkynyl and Ar, all of which are optionally substituted with one or more substituents selected from the group consisting of: -OH and halogen, or
(ii) when attached to the same nitrogen atom R6 and R7 can join together to form a ring selected from the group consisting of: piperidyl, morpholynyl, piperazinyl and pyrrolidyl; R1 is hydrogen, or selected from: linear or branched Ci^alkyl, -(CH2)nC3_7cycloalkyl, linear or branched C2-6alkenyl, linear or branched C2_6alkynyl and -(CH2)n r, all of which are optionally substituted with one or more substituents selected from the group consisting of: -OH, -OR6, -CONR6R7, -NR R7, -COR6, -CO R6, -SO2NHR6, - NHCOR6 and halogen, where n, R6 and R7 have the same meaning as above; and R2 and R3 are
(i) hydrogen, or independently selected from: H, linear or branched Cj.galkyl, -(CH2)nC3_ cycloalkyl, linear or branched C2-6al enyl, linear or branched C2_6alkynyl and -(CH2)nAr, all of which are optionally substituted with one or more substituents selected from the group consisting of: -OH, -OR6, -CONR R7, - NR6R7, -COR6, -CO2R6 -SO2NHR6, -NHCOR6 and halogen, where n, R6 and R7 have the same meaning as above, (ii) R2 and R3 are joined together to form a non aromatic saturated or unsaturated C3_i2cycloalkyl> optionally containing one or two heteroatoms, and optionally substituted with one or more substituents selected from the group consisting of: ethylenedioxy, linear or branched C^galkyl, - (CH2)nC3_7cycloalkyl, linear or branched C2-6&l enyl, linear or branched C2-6alkynyl, -(CH2)nAr, -OH, -OR6, -CONR6R7, -COR6, -CO R6, - SO2NHR6, -NHCOR6 and halogen, where n, R6 and R7 have the same meaning as above, or (iii) R2 and R3 are joined together to form an aromatic ring selected from the group consisting of: phenyl, naphthyl, furyl, pyrrolyl, thienyl, isothiazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrazinyl, pyrimidyl, pyridazinyl, carbazolyl, indolyl, quinolyl and purinyl, all of which are optionally substituted with one or more substituents selected from the group consisting of: halogen, -OH, linear or branched C^alkyl, -(CH2)nC3-7cycloalkyl, linear or branched C2-6alkenyl, -(CH2)nPh, -O-Cι.6alkyl, -CONR6R7, - NR6R7, -COR6, -CO R6, -SO2NHR6, -NHCOR6 and halogen, where n, R6 and R7 have the same meaning as above; or a pharmaceutically acceptable salt, hydrate or solvate thereof; except 2,3 ,7 ,8 ,9, 10-Hexahydro-4-methyl- 1 H- [ 1 ]benzothieno[2,3-b]pyrazolo[3 ,4- d]pyridin-3-one and 8,8-Ethylenedioxy-2,3,7,8,9, 10-hexahydro-4-methyl-lH- [l]benzothieno[2,3-b]pyrazolo[3,4-d]pyridin-3-one; but including pharmaceutically acceptable salts, hydrates and solvates of 2,3,7,8,9, 10-Hexahydro-4-methyl-lH- [l]benzothieno[2,3-b]pyrazolo[3,4-d]pyridin-3-one and 8,8-Ethylenedioxy- 2,3,7,8,9, 10-hexahydro-4-methyl-lH-[l]benzothieno[2,3-b]pyrazolo[3,4-d]pyridin- 3-one. Preferred among the presently invented Formula (I) compounds are those having the following Formula (II):
Figure imgf000006_0001
OD wherein:
X is O or NR5, where R5 is hydrogen, or selected from: linear or branched Cj.galkyl, -(CH2)nC3-7cycloalkyl, linear or branched C2_6al enyl, linear and branched C2-6 l ynyl or -(CH2)n r, where n is 0 to 6; Rl is hydrogen, or selected from: linear or branched C^alkyl, -(CH2)nC3_7cycloalkyl, linear or branched C2-6al enyl, linear or branched C2-6alkynyl and -(CH2)nAr, where n has the same meaning as above; and
R2 and R3 are
(i) hydrogen, or independently selected from: linear or branched C^alkyl, -(CH2)nC3_ 7cycloalkyl, linear or branched C2-6alkenyl, linear or branched C2-6al ynyl and -(CH2)nAr, where n has the same meaning as above, (ii) R2 and R3 are joined together to form a non aromatic saturated or unsaturated C3_i2cycl°al yl, optionally containing one nitrogen atom, and optionally substituted with one substituent selected from the group consisting of: ethylenedioxy , linear or branched C \ -β-dky -(CH2)nC3_
7cycloalkyl, linear or branched C2-6 l enyl, linear or branched C2-6 l ynyl, -(CH2)nAr, -OH, -OR6, -CONR6R7, -COR6, -CO2R6, -SO2NHR6, - NHCOR6 and halogen, where n has the same meaning as above, or (iii) R2 and R3 are joined together to form an aromatic ring selected from the group consisting of: phenyl, naphthyl, furyl, pyrrolyl, thienyl, isothiazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrazinyl, pyrimidyl, pyridazinyl, carbazolyl, indolyl, quinolyl and purinyl, all of which are optionally substituted with one or more substituents selected from the group consisting of: halogen, -OH, linear or branched Cj.galkyl, -(CH2)nC3_7cycloalkyl, linear or branched C2-6alkenyl, -(CH2)nPh, -O-Cι_6alkyl and halogen, where n has the same meaning as above; or a pharmaceutically acceptable salt, hydrate or solvate thereof; except 2,3,7,8,9,10-Hexahydro-4-methyl-lH-[l]benzothieno[2,3-b]pyrazolo[3,4- d]pyridin-3-one and 8,8-Ethylenedioxy-2,3,7,8,9,10-hexahydro-4-methyl-lH-
[l]benzothieno[2,3-b]pyrazolo[3,4-d]pyridin-3-one; but including pharmaceutically acceptable salts, hydrates and solvates of 2,3,7,8,9,10-Hexahydro-4-methyl-lH-
[ 1 ]benzothieno[2,3-b]pyrazolo[3,4-d]pyridin-3-one and 8,8-Ethylenedioxy- 2,3,7,8,9,10-hexahydro-4-methyl-lH-[l]benzothieno[2,3-b]pyrazolo[3,4-d]pyridin-
3-one.
Preferred among the presently invented Formula (II) compounds are those in which:
X is NR5, where R5 is hydrogen, or selected from: linear or branched Cj^alkyl, C3_7cycloalkyl and phenyl;
Rl is hydrogen, or selected from: linear or branched Cj.galkyl, C3_7cycloalkyl and phenyl; and
R2 and R3 are (i) hydrogen, or independently selected from: linear or branched Cj.galkyl, C3_7cycloalkyl and phenyl,
(ii) R2 and R3 are joined together to form a non aromatic saturated or unsaturated C5_7cycloalkyl, optionally containing one nitrogen heteroatom, and optionally substituted with one or more substituents selected from the group consisting of: ethylenedioxy, linear or branched Ci _6alkyl, C3_7cycloalkyl, phenyl,-
OH, -OR6, -CONR6R7, -COR6, -CO2R6, -SO2NHR6, - NHCOR6 and halogen, or
(iii) R2 and R3 are joined together to form a phenyl ring, optionally substituted with one or more substituents selected from the group consisting of: halogen, -OH, linear or branched Ci.galkyl, C3_7cycloalkyl and phenyl; except 2,3,7,8,9, 10-Hexahydro-4-methyl- 1 H-[ 1 ]benzothieno[2,3-b]pyrazolo[3,4- d]pyridin-3-one and 8,8-Ethylenedioxy-2,3,7,8,9, 10-hexahydro-4-methyl-lH- [l]benzothieno[2,3-b]pyrazolo[3,4-d]pyridin-3-one.
Preferred among the presently invented compounds are: 2,3-Dihydro-4-methyl-lH-[l]benzothieno[2,3-b]pyrazolo[3,4-d]pyridin-3- one and pharmaceutically acceptable salts, hydrates and solvates thereof;
A pharmaceutically acceptable salt, hydrate or solvate of 2,3,7,8,9,10- Hexahydro-4-methyl-lH-[l]benzothieno[2,3-b]pyrazolo[3,4-d]pyridin-3-one; 1 ,4-Dimethyl-8,8-ethylenedioxy-2,3,7,8,9, 10-hexahydro- 1H- [l]benzothieno[2,3-b]pyrazolo[3,4-d]pyridin-3-one and pharmaceutically acceptable salts, hydrates and solvates thereof;
A pharmaceutically acceptable salt, hydrate or solvate of 8,8-Ethylenedioxy- 2,3,7,8,9, 10-hexahydro-4-methyl-lH-[l]benzothieno[2,3-b]pyrazolo[3,4-d]pyridin- 3-one; 8-ter/-Butoxycarbonyl-2,3,7,8,9,10-hexahydro-4-methyl-lH- pyrido[4',3':4,5]thieno[2,3-b]pyrazolo[3,4-d]pyridin-3-one and pharmaceutically acceptable salts, hydrates and solvates thereof; and
2,3,7,8,9, 10-Hexahydro-4-methyl-lH-pyrido[4',3':4,5]thieno[2,3- b]pyrazolo[3,4-d]pyridin-3-one and pharmaceutically acceptable salts, hydrates and solvates thereof.
Compounds of the present invention that enhance erythropoiesis have the following Formula (III):
Figure imgf000009_0001
wherein:
X is O or NR5, where R5 is hydrogen, or selected from: linear or branched Cj.galkyl, -(CH2)nC3_7cycloalkyl, linear or branched C2_6alkenyl, linear and branched C2-6alkynyl or -(CH2)nAr, all of which are optionally substituted with one or more substituents selected from the group consisting of: -OH, -OR6, -CONR6R7, -NR6R7, -COR6, - CO2R6, -SO2NHR6, -NHCOR6 and halogen, where n is 0 to 6, and R6 and R7 are: (i) hydrogen, or independently selected from: H, linear or branched C^galkyl, C3. 7cycloalkyl, linear or branched C2-6 lkenyl, linear or branched C2- galkynyl and Ar, all of which are optionally substituted with one or more substituents selected from the group consisting of: -OH and halogen, or
(ii) when attached to the same nitrogen atom R6 and R7 can join together to form a ring selected from the group consisting of: piperidyl, morpholynyl, piperazinyl and pyrrolidyl; Rl is hydrogen, or selected from: linear or branched Cj.galkyl, -(CH2)nC3-7cycloalkyl, linear or branched C2-6alkenyl, linear or branched C2_6alkynyl and -(CH2)nAr, all of which are optionally substituted with one or more substituents selected from the group consisting of: -OH, -OR6, -CONR6R7, -NR R7, -COR6, -CO2R6, -SO NHR6, - NHCOR6 and halogen, where n, R6 and R7 have the same meaning as above; and R2 and R3 are (i) hydrogen, or independently selected from: H, linear or branched C^alkyl, -(CH2)nC3_ 7cycloalkyl, linear or branched C2-6alkenyl, linear or branched C2_6alkynyl and -(CH2)nAr, all of which are optionally substituted with one or more substituents selected from the group consisting of: -OH, -OR6, -CONR6R7, - NR6R7, -COR6, -CO2R6, -SO NHR6, -NHCOR6 and halogen, where n, R6 and R7 have the same meaning as above, (ii) R2 and R3 are joined together to form a non aromatic saturated or unsaturated C3. ^cycloalkyl, optionally containing one or two heteroatoms, and optionally substituted with one or more substituents selected from the group consisting of: ethylenedioxy, linear or branched C^alkyl, - (CH2)nC3-7cycloalkyl, linear or branched C2-6alkenyl, linear or branched
C2-6alkynyl, -(CH2)nAr, -OH, -OR6, -CONR6R7, -COR6, -CO2R6, - SO2NHR6, -NHCOR6 and halogen, where n, R6 and R7 have the same meaning as above, or (iii) R2 and R3 are joined together to form an aromatic ring selected from the group consisting of: phenyl, naphthyl, furyl, pyrrolyl, thienyl, isothiazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrazinyl, pyrimidyl, pyridazinyl, carbazolyl, indolyl, quinolyl and purinyl, all of which are optionally substituted with one or more substituents selected from the group consisting of: halogen, -OH, linear or branched Cι_galkyl, -(CH2)nC3-7cycloalkyl, linear or branched C2-6alkenyl, -(CH2)nPh, -O-Ci.galkyl, -CONR6R7, - NR6R7, -COR6, -CO2R6, -SO2NHR6, -NHCOR6 and halogen, where n, R6 and R7 have the same meaning as above; or a pharmaceutically acceptable salt, hydrate or solvate thereof. Preferred among above Formula (III) compounds of the present invention that enhance erythropoiesis are those having the following Formula (IV):
Figure imgf000011_0001
wherein:
X is O or NR5, where R5 is hydrogen, or selected from: linear or branched C^galkyl, -(CH2)nC3_7cycloalkyl, linear or branched C2-6alkenyl, linear and branched C2_6 lkynyl or -(CH2)nAr, where n is 0 to 6; Rl is hydrogen, or selected from: linear or branched Cj.galkyl, -(CH2)nC3-7cycloalkyl, linear or branched C2_6alkenyl, linear or branched C2-6alkynyl and -(CH2)nAr, where n has the same meaning as above; and
R2 and R3 are
(i) hydrogen, or independently selected from: linear or branched Ci .^alkyl, - CH2)nC3_ 7cycloalkyl, linear or branched C2-6alkenyl, linear or branched C2-6 lkynyl and -(CH2)nAr, where n has the same meaning as above, (ii) R2 and R3 are joined together to form a non aromatic saturated or unsaturated C3_i2cycl°alkyl, optionally containing one nitrogen atom, and optionally substituted with one substituent selected from the group consisting of: ethylenedioxy, linear or branched Cι_6alkyl, -(CH2)nC3_
7cycloalkyl, linear or branched C2-6alkenyl, linear or branched C2-6alkynyl, -(CH2)nAr, -OH, -OR6, -CONR6R7, -COR6, -CO2R6, -SO2NHR6, - NHCOR6 and halogen, where n has the same meaning as above, or (iii) R2 and R3 are joined together to form an aromatic ring selected from the group consisting of: phenyl, naphthyl, furyl, pyrrolyl, thienyl, isothiazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrazinyl, pyrimidyl, pyridazinyl, carbazolyl, indolyl, quinolyl and purinyl, all of which are optionally substituted with one or more substituents selected from the group consisting of: halogen, -OH, linear or branched C^galkyl, -(CH2)nC3_7cycloalkyl, linear or branched C2_6al enyl, -(CH2)nPh, -O-Cj.galkyl and halogen, where n has the same meaning as above; or a pharmaceutically acceptable salt, hydrate or solvate thereof. Preferred among the presently invented Formula (IV) compounds are those in which: X is NR5, where R5 is hydrogen, or selected from: linear or branched Ci^alkyl, C3_7cycloalkyl and phenyl;
Rl is hydrogen, or selected from: linear or branched Cj^alkyl, C3_7cycloalkyl and phenyl; and
R2 and R3 are
(i) hydrogen, or independently selected from: linear or branched C^galkyl, C3_7cycloalkyl and phenyl, (ii) R2 and R3 are joined together to form a non aromatic saturated or unsaturated C5_7cycloalkyl, optionally containing one nitrogen heteroatom, and optionally substituted with one or more substituents selected from the group consisting of: ethylenedioxy, linear or branched C^galkyl, C3_7cycloalkyl, phenyl,-
OH, -OR6, -CONR6R7, -COR6, -CO2R6, -SO2NHR6, - NHCOR6 and halogen, or
(iii) R2 and R3 are joined together to form a phenyl ring, optionally substituted with one or more substituents selected from the group consisting of: halogen, -OH, linear or branched Cι_6alkyl, C3_7cycloalkyl and phenyl; except 2,3,7,8,9,10-Hexahydro-4-methyl-lH-[l]benzothieno[2,3-b]pyrazolo[3,4- d]pyridin-3-one and 8,8-Ethylenedioxy-2,3,7,8,9,10-hexahydro-4-methyl-lH-
[ 1 ]benzothieno[2,3-b]pyrazolo[3,4-d]pyridin-3-one.
Preferred compounds of the present invention that enhance erythropoiesis are:
2,3,7,8,9,10-Hexahydro-4-methyl-lH-[l]benzothieno[2,3-b]pyrazolo[3,4- d]pyridin-3-one and pharmaceutically acceptable salts, hydrates and solvates thereof; 2,3-Dihydro-4-methyl-lH-[l]benzothieno[2,3-b]ρyrazolo[3,4-d]pyridin-3- one and pharmaceutically acceptable salts, hydrates and solvates thereof;
8,8-Ethylenedioxy-2,3,7,8,9,10-hexahydro-4-methyl-lH-[l]benzothieno[2,3- b]pyrazolo[3,4-d]pyridin-3-one and pharmaceutically acceptable salts, hydrates and solvates thereof; l,4-Dimethyl-8,8-ethylenedioxy-2,3,7,8,9,10-hexahydro-lH- [l]benzothieno[2,3-b]pyrazolo[3,4-d]pyridin-3-one and pharmaceutically acceptable salts, hydrates and solvates thereof;
8-rert-Butoxycarbonyl-2,3,7,8,9,10-hexahydro-4-methyl-lH- pyrido[4',3':4,5]thieno[2,3-b]pyrazolo[3,4-d]pyridin-3-one and pharmaceutically acceptable salts, hydrates and solvates thereof; and
2,3,7,8,9, 10-Hexahydro-4-methyl- lH-pyrido[4',3':4,5]thieno[2,3- b]pyrazolo[3,4-d]pyridin-3-one and pharmaceutically acceptable salts, hydrates and solvates thereof. Compounds of Formula (III) are included in the pharmaceutical compositions of the invention and used in the methods of the invention.
By the term "AR" as used herein is meant phenyl, naphthyl, furyl, pyrrolyl, thienyl, isothiazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrazinyl, pyrimidyl, pyridazinyl, carbazolyl, indolyl, quinolyl or purinyl.
By the term "Cx.yCycloalkyl" as used herein is meant a nonaromatic, unsaturated or saturated, cyclic or poly cyclic compound having from x to y carbons. When indicated, the term "Cx.yCycloalkyl" can include one or two heteroatoms. Examples of Cx_ycycloalkyl as used herein include: cylcohexyl and cyclopentyl.
By the term "heteroatom" as used herein is meant O or N. By the term "halogen" as used herein is meant F, Cl, Br or I. Formula (I) compounds are prepared as shown in Scheme I below provided that the 'R' substituents do not include any such substituents that render inoperative the Scheme I process.
Scheme (I)
Preparation of Compounds of Formula fl) Scheme (I) outlines the preparation of Fromula (I) compounds from Formula (2) compounds. A ketone of Formula (2) R2
° (2) where R2 and R3 are as described above; is reacted with ethyl cyanoacetate, in a solvent, such as toluene, at reflux in the presence of of an amine, such as diethylamine, with azeotropic removal of water using a Dean-Stark apparatus to yield a cyano ester of Formula (3)
Figure imgf000015_0001
Reacting the cyano ester of Formula (3) with elemental sulfur in a solvent, preferably ethanol, in the presence of an amine, such as diethylamine, affords the thiophene-3-carboxylate of Formula (4)
Figure imgf000015_0002
Compounds of Formula (4) are treated with a 3 -ethoxy crotonate of Formula
(5)
Figure imgf000015_0003
where R, is as described above; in a suitable solvent ,such as toluene, at reflux in the presence of an acid catalyst, such as camphorsulfonic acid, and with azeotropic removal of water using a Dean- Stark trap. The resulting material is treated with 1 M sodium ethoxide solution and reflux to provide a thieno[2,3-b]pyridine of Formula (6)
Figure imgf000015_0004
Treatment of the compound of Formula (6) with phosphorous oxychloride at reflux provideds the chlorothieno[2,3-b]pyridine of Formula (7)
Figure imgf000016_0001
Treatment of the compound of Formula (6) with triflic anhydride in pyridine at 0 °C with aqueous work-up provides a triflate derivative of Formula (8)
Figure imgf000016_0002
Reaction of either a compound of Formula (7) or compound of Formula (8) with a hydrazine derivative of Formula (9)
H
/
5^N^NH. R 2 (9) where R5 is as described above; in a solvent, such as methanol, at reflux provides compounds of Formula (I), wherein X is NR5.
Altemativately, treatment of either compound of Formula (7) or compound of
Formula (8) with the hydroxylamine of Structure (10)
H
HO H ( 10) in a solvent, such as methanol, at reflux and in the presence of a base, such as triethylamine or sodium hydroxide, provides compounds of Formula (I), wherein X is O.
Pharmaceutically acceptable salts, hydrates and solvates of the compounds within the scope of this invention are formed when appropriate by methods well known to those of skill in the art. In preparing the presently invented compounds of Formula (I), novel intermediates of the following Formula (V) are synthesized:
Figure imgf000017_0001
in which Rl is as described in Formula (I); and
R2 and R3 are joined together to form a non aromatic saturated or unsaturated C3. ^cycloalkyl, optionally containing one or two heteroatoms, and optionally substituted with one or more substituents selected from the group consisting of: ethylenedioxy, linear or branched C^galkyl, -(CH2)nC3_7cycloalkyl, linear or branched C2-6alkenyl, linear or branched C2-6alkynyl, -(CH2)nAr, -OH, -OR6, - CONR6R7, -COR6, -CO2R6, -SO2NHR6, -NHCOR6 and halogen, where n, R6 and R7 have the same meaning as in Formula (I).
A preferred process for preparing a compound of Formula (I)
Figure imgf000017_0002
in which X is NR5 and NR5, Rl, R2 and R3 are as described in Formula (I) above, including the exceptions, and pharmaceutically acceptable salts, hydrates and solvates thereof comprises reacting a compound of the Formula
Figure imgf000017_0003
in which Rl, R2 and R3 are as described above with a hydrazine derivative of the formula
Figure imgf000017_0004
where R5 is as described in Formula (I) above; in a solvent, such as methanol, at reflux and thereafter optionally forming a pharmaceutically acceptable salt, hydrate or solvate thereof.
A preferred process for preparing a compound of Formula (I)
Figure imgf000018_0001
in which X is NR5 and NR5, R*, R2 and R3 are as described in Formula (I) above, including the exceptions, and pharmaceutically acceptable salts, hydrates and solvates thereof comprises reacting a compound of the Formula
Figure imgf000018_0002
in which Rl, R2 and R3 are as described above with a hydrazine derivative of the formula
H
,N- •NH„
RJ 2 where R5 is as described in Formula (I) above; in a solvent, such as methanol, at reflux and thereafter optionally forming a pharmaceutically acceptable salt, hydrate or solvate thereof.
A preferred process for preparing a compound of Formula (I)
Figure imgf000018_0003
in which X is O and R*, R2 and R3 are as described in Formula (I) above, including the exceptions, and pharmaceutically acceptable salts, hydrates and solvates thereof comprises reacting a compound of the Formula
Figure imgf000019_0001
in which R1, R2 and R3 are as described above with the hydroxylamine of the
Structure
H
HO^ H in a solvent, such as methanol, at reflux and in the presence of a base, such as triethylamine or sodium hydroxide, and thereafter optionally forming a pharmaceutically acceptable salt, hydrate or solvate thereof.
A preferred process for preparing a compound of Formula (I)
Figure imgf000019_0002
in which X is O and R*. R2 and R3 are as described in Formula (I) above, including the exceptions, and pharmaceutically acceptable salts, hydrates and solvates thereof comprises reacting a compound of the Formula
Figure imgf000019_0003
in which Rl, R2 and R3 are as described above with the hydroxylamine of the Structure
H
-N>
HO' Η in a solvent, such as methanol, at reflux and in the presence of a base, such as triethylamine or sodium hydroxide, and thereafter optionally forming a pharmaceutically acceptable salt, hydrate or solvate thereof. Because the pharmaceutically active compunds of the present invention enhance erythropoiesis they have therapeutic utility in treating anemias, cytopenias and other conditions with depressed erythrocyte production.
In determining the potency of the compounds of this invention to enhance erythropoiesis the following procedure was employed.
Effect of Compounds of the Present Invention on the Cell Growth of the Erythropoietin (EPO) Dependent UT7/EPO Human Cell Line
UT7/EPO cells express human EPO receptors on their cell surface and respond to EPO by cell proliferation. Proliferation of UT7/EPO cells in response to EPO or to compounds of the present invention was quantitated using a MTT assay as described in T. Mosmann (1983) J. Immunol. Methods Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays 65:55-63. UT7/EPO cells were grown in growth medium ( Iscove's Modified Dulbecco's Medium with L-glutamine and 25 mM HEPES buffer) (IMDM medium) with 0.4U/ml recombinant human EPO (Amgen) and 10% fetal bovine serum (FBS) to a cell density of approximately 5 x 105 cells/ml. Cells were collected by centrifugation ( ~ 600 x g) and washed twice in IMDM without EPO or FBS. The cells were resuspended at 5 x 105 cells/ml in IMDM medium with 10% FBS or serum-free medium. One hundred microliter aliquots were added to wells in a 96 well microtiter plate. A compound of the present invention (or EPO) was added to the wells by serial dilution, maintaining a final volume of 0.1 ml. The treated cells were incubated in a humidified incubator at 37°C and 5% CO2 for 2 - 3 days. At the end of the incubation period, 0.04 mg MTT [(3-[4,5-Dimthylthiazol-2-y]-2,5- diphenyltetrazolium bromide] was added to every well in a volume of 0.025 ml and incubated for 4 hours. The MTT reaction was stopped by addition of 10% SDS in 0.0 IN HCL and solubilized overnight at 37°C. Proliferation was quantitated colorimetrically at 570/750 nM using a BioTek II Microplate Reader. The increase in OD 570/750 is proportional to cell growth.
Compounds within the scope of this invention have have been tested and have shown an EC50 activity from 1 (uM) to > 66 (uM) of MTT activity in
UT7 EPO cells. Particularly preferred among the compounds of the invention and the compounds used in the invented pharmaceutical compositions and invented methods are:
2,3-Dihydro-4-methyl-lH-[l]benzothieno[2,3-b]pyrazolo[3,4-d]pyridin-3- one and pharmaceutically acceptable salts, hydrates and solvates thereof; A pharmaceutically acceptable salt, hydrate or solvate of 2,3,7,8,9,10-
Hexahydro-4-methyl-lH-[l]benzothieno[2,3-b]pyrazolo[3,4-d]pyridin-3-one; l,4-Dimethyl-8,8-ethylenedioxy-2,3,7,8,9,10-hexahydro-lH- [l]benzothieno[2,3-b]pyrazolo[3,4-d]pyridin-3-one and pharmaceutically acceptable salts, hydrates and solvates thereof; A pharmaceutically acceptable salt, hydrate or solvate of 8,8-Ethylenedioxy-
2,3,7,8,9,10-hexahydro-4-methyl-lH-[l]benzothieno[2,3-b]ρyrazolo[3,4-d]pyridin- 3-one;
8-tert-Butoxycarbonyl-2,3,7,8,9, 10-hexahydro-4-methyl- 1H- pyrido[4',3':4,5]thieno[2,3-b]pyrazolo[3,4-d]pyridin-3-one and pharmaceutically acceptable salts, hydrates and solvates thereof; and
2,3,7,8,9,10-Hexahydro-4-methyMH-pyrido[4',3*:4,5]thieno[2,3- b]pyrazolo[3,4-d]pyridin-3-one and pharmaceutically acceptable salts, hydrates and solvates thereof.
Compounds within the scope of this invention have also stimulated proliferation of UT7/EPO cells in the presence of a suboptimal concentration of EPO.
The pharmaceutically active compounds within the scope of this invention are useful in enhancing erythropoiesis in mammals, including humans, in need thereof. The pharmaceutically active compounds of the present invention are incoφorated into convenient dosage forms such as capsules, tablets, or injectable preparations. Solid or liquid pharmaceutical carriers are employed. Solid carriers include, starch, lactose, calcium sulfate dihydrate, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate and stearic acid. Liquid carriers include syrup, peanut oil, olive oil, saline, and water. Similarly, the carrier or diluent may include any prolonged release material, such as glyceryl monostearate or glyceryl distearate, alone or with a wax. The amount of solid carrier varies widely but, preferably, will be from about 25 mg to about lg per dosage unit. When a liquid carrier is used, the preparation will be in the form of a syrup, elixir, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampoule, or an aqueous or nonaqueous liquid suspension.
The pharmaceutical preparations are made following conventional techniques of a pharmaceutical chemist involving mixing, granulating, and compressing, when necessary, for tablet forms, or mixing, filling and dissolving the ingredients, as appropriate, to give the desired oral or parenteral products. Doses of the presently invented pharmaceutically active compounds in a pharmaceutical dosage unit as described above will be an efficacious, nontoxic quantity preferably selected from the range of 0.001 mg per kg and 100.0 mg per kg of subject body weight, preferably 0.001 - 10 mg kg. The active compounds may be administered to a patient in need of enhanced erythropoiesis by any conventional route of administration, including, but not limited to, intravenous, intramuscular, oral, subcutaneous, intradermal, and parenteral. When treating a human patient in need of enhanced erythropoiesis, the selected dose is administered preferably from 1-6 times daily, orally or parenterally. Preferred forms of parenteral administration include topically, rectally, transdermal ly, by injection and continuously by infusion. Oral dosage units for human administration preferably contain from 0.05 to 500 mg of active compound. Oral administration, which uses lower dosages is preferred. Parenteral administration, at high dosages, however, also can be used when safe and convenient for the patient.
Optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the particular pharmaceutically active compound in use, the strength of the preparation, the mode of administration, and the advancement of the disease condition. Additional factors depending on the particular patient being treated will result in a need to adjust dosages, including patient age, weight, diet, and time of administration. The method of this invention of enhancing erythropoiesis in mammals, including humans, comprises administering to a subject in need of such therapy an effective erythropoiesis enhancing amount of a pharmaceutically active compound of the present invention.
The invention also provides for the use of a compound of Formula (III) in the manufacture of a medicament for use in enhancing erythropoiesis. The invention also provides for a pharmaceutical composition for use in the treatment of anemias which comprises a compound of Formula HI and a pharmaceutically acceptable carrier.
The invention also provides for a pharmaceutical composition for use in the treatment of cytopenias which comprises a compound of Formula III and a pharmaceutically acceptable carrier.
The invention also provides for a process for preparing a pharmaceutical composition containing a pharmaceutically acceptable carrier or diluent and a compound of Formula III which comprises bringing the compound of Formula III into association with the pharmaceutically acceptable carrier or diluent. No unacceptable toxicological effects are expected when compounds of the invention are administered in accordance with the present invention.
In addition, the pharmaceutically active compounds of the present invention can be co-administered with further active ingredients, such as other compounds known to enhance erythropoiesis. Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent.
The following Examples are, therefore, to be construed as merely illustrative and not a limitation of the scope of the present invention in any way.
Experimental Details Example 1
Preparation of 2.3.7.8.9.10-Hexahvdro-4-methyl-lH-πibenzothienor2.3- blpvrazolor3.4-dlpyridin-3-one
Figure imgf000024_0001
a) Ethyl 4-Hydroxy-2-methyl-5,6,7,8-tetrahydro-[ 1 ]benzothieno[2,3-b]pyridine-2- carboxylate A solution of ethyl 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3- carboxylate (8.9 g, 39 mmol) and ethyl 3-ethoxycrotonate (12.4 g, 78 mmol) in toluene (300 mL) was treated with camphorsulfonic acid (0.78 g, 3.4 mmol) and the reaction mixture was heated at reflux for 3 h using a Dean Stark trap. The mixture was then cooled to room temperature and was subsequently treatedwith a freshly prepared 1 M solution of sodium ethoxide (48 mL, 48 mmol). After addition was complete the reaction mixture was heated at reflux for 3 h. The mixture was cooled, concentrated and the residue dissolved in ethyl acetate. Acetic acid (2 mL) was added, solvent evaporated and resulting solid triturated with methanol to yield the title compound as an off-white solid (8.4 g, 74%). mp 140 °C; »H NMR (400 MHz, CDC13) δ 4.48 (q, J = 7.2 Hz, 2 H), 3.04 (br s, 2 H), 2.81 (s, 3 H), 2.80 (br s, 2 H), 1.87 (br s, 4 H), 1.47 (t, J = 7.2 Hz, 3 H); Anal. Calcd. for C15H17NO3S: C, 61.83; H, 5.88; N, 4.81; Found: C, 61.69; H, 5.81; N, 4.73.
b) Ethyl 4-Chloro-2-methyl-5,6,7,8-tetrahydro-[ l]benzothieno[2,3-b]pyridine-2- carboxylate
A solution of compound of Example 1(a) (8.0 g, 27.4 mmol) in phosphorus oxychloride (100 mL) was refluxed for 3.5 hours. The phosphorus oxychloride was removed under vacuum and the residual oil was dissolved in ethyl acetate, washed with 5% aqueous sodium bicarbonate and dried over anhydrous sodium sulfate. Evaporation of the solvent provided the title compound as a crystalline solid (8.5 g, 95%). mp 65-66 °C; !H NMR (400 MHz, CDC13) δ 4.47 (q, J = 7.1 Hz, 2 H), 3.10 (br s, 2 H), 2.85 (br s, 2 H), 2.60 (s, 3 H), 1.89 (br s, 4 H), 1.43 (t, J = 7.1 Hz, 3 H); Anal. Calcd. for C15H16ClNO2S.5/4H2O: C, 57.73; H, 5.25; N, 4.49; Found: C, 57.69; H, 5.08; N, 4.30.
c) 2,3,7,8,9,10-Hexahydro-4-methyl-lH-[l]benzothieno[2,3-b]ρyrazolo[3,4- d]pyridin-3-one Hydrochloride Salt
A solution of compound of Example 1(b) (2.0 g, 6.4 mmol) in methanol (50 mL) was treated with hydrazine monohydrate (10 mL) and the resulting mixture was heated at reflux for 16 h. The reaction was poured over diluted aqueous hydrochloric acid and the title compound precipitated as a yellow solid (1.8 g). l NMR (400 MHz, d4-MeOH) δ 3.01 (br s, 2 H), 3.00 (s, 3 H), 2.92 (br s, 2 H), 2.00 (br s, 4 H); Anal. Calcd. for C^H^OS.HCl.lΛH^O: C, 52.00; H, 4.87; N, 13.99; Found: C, 51.92; H, 5.01; N, 13.70.
Example 2
Preparation of 2.3-Dihydro-4-methyl- lH-f 1 lbenzothienor2.3-b1pyrazolor3.4- dlpyridin-3-one
Figure imgf000025_0001
a) Ethyl 4-Chloro-2-methyl-[ 1 ]benzothieno[2,3-b]pyridine-2-carboxylate
A solution of compound of Example 1(b) (400 mg, 1.3 mmol) in toluene (20 mL) was treated with DDQ (1.8 g, 8.0 mmol) and the resulting suspension was refluxed at 100 °C for 24 h. The mixture was filtered off, the solvent evaporated and the crude material was purified by flash chromatography (silica gel, 9:1 hexane: ethyl acetate) to provide a the title compound as a solid material (400 mg): mp 111- 112 °C; Anal. Calcd. for C15H12ClNO2S; C, 58.92; H, 3.96; N, 4.58; Found: C, 58.78; H, 3.84; N, 4.56. b) 2,3-Dihydro-4-methyl-lH-[l]benzothieno[2,3-b]pyrazolo[3,4-d]pyridin-3-one
A solution of compound of Example 2(a) (160 mg, 0.52 mmol) in methanol (10 mL) was treated with hydrazine monohydrate (2 mL) and the resulting mixture was heated at reflux for 24 h. After concentrating the solution under reduced pressure it was poured over diluted aqueous hydrochloric acid; the title compound precipitated as a yellow solid (140 mg, 90%): Anal. Calcd. for C13H9N3OS.0.25 H2O: C, 59.01; H, 3.81; N, 15.90; Found: C, 59.38; H, 3.80; N, 15.58.
Example 3
Preparation of 8.8-Ethvlenedioxv-2.3.7.8.9.10-hexahvdro-4-methvl-lH- rilbenzothienor2.3-blpvrazolor3.4-d1pvridin-3-one
Figure imgf000026_0001
a) Ethyl 2-Cyano-2-(4,4,-ethylenedioxycyclohexylidene)acetate
To a mixture of 1,4 cyclohexanedione monoethylene ketal (25 g, 0.160 mol) and ethyl cyanoacetate (18 g, 0.160 mol) in toluene (400 mL) was added dropwise diethylamine (25 g, 0.337 mol) at room temperature. The reaction mixture was heated at reflux overnight (using a Dean Stark apparatus). The mixture was cooled and partitioned with ethyl acetate and saturated aqueous sodium bicarbonate (3x).
The organic extracts were dried over sodium sulfate, filtered, concentrated in vacuo and recrystallized from ethanol to yield the title compound as an white solid (15.8 g, 45%). mp 80-81 °C; »H NMR (400 MHz, CDC13) δ 4.28 (q, J = 7.2 Hz, 2 H), 4.00
(s, 4 H), 3.18 (t, J = 6.5 Hz, 2 H), 2.85 (t, J = 6.5 Hz, 2 H), 1.89 (t, J = 6.5 Hz, 2 H),
1.82 (t, J = 6.5 Hz, 2 H), 1.35 (t, J = 7.1 Hz, 3 H). b) Ethyl 2-Amino-6,6-ethylenedioxy-4,5,6,7-tetrahydrobenzo[b]thiophene-3- carboxylate
To a suspension of compound of Example 3(a) (10 g, 45.6 mmol), sulfur (1.6 g, 50.2 mmol) in ethanol (164 mL) at 0 °C, was added dropwise a solution of diethylamine (3.6 g, 50.2 mmol) in ethanol (26 mL). The resulting solution stirred at 0 °C for 1 h, then at room temperature for 3.5 h. The reaction mixture was quenched with ethyl acetate and partitioned with saturated aqueous ammonium chloride solution. The aqueous phase was extracted with ethyl acetate, and the organic extracts were washed with brine. The combined organic extracts were dried over sodium sulfate, filtered, concentrated in vacuo and chromatographed (silica gel, gradient 5 to 10% CH2Cl2:EtOAc) to yield the title compound as an oil (11.3 g, 87%). lH NMR (400 MHz, CDC13) δ 4.25 (q, J = 7.1 Hz, 2 H), 4.02(s, 4 H), 2.92 (t, J = 6.5 Hz, 2 H), 2.74 (s, 2 H), 1.90 (t, J = 6.6 Hz, 2 H), 1.33 (t, J = 7.1 , 3 H).
c) Ethyl 7,7-Ethylenedioxy-4-hydroxy-2-methyl-5,6,7,8-tetrahydro- [ 1 ]benzothieno[2,3-b]pyridine-2-carboxylate
To a solution of compound of Example 3(b) (1 1.2 g, 39.5 mmol) in toluene (307 mL) at room temperature was added ethyl 3-ethoxycrotonate (12.4 g, 78.6 mmol) and camphorsulfonic acid (0.78 g, 3.4 mmol). The reaction mixture was heated at reflux for 3.5 h using a Dean Stark trap. The mixture was then cooled, and to it was added dropwise a freshly prepared solution of 1 M sodium ethoxide (49 mL). Once the addition was complete the reaction mixture was heated at reflux for 3 h. The mixture was cooled and the precipitate was filtered. After dissolving the salt in methanol (60 mL), it was added water (500 mL) and acetic acid (2 mL) to yield the title compound as a yellow solid (10.4 g, 76%). mp 94-95 °C; l NMR (400 MHz, CDC13) δ 4.48 (q, J = 7.1 Hz, 2 H), 4.06(s, 4 H), 3.26 (t, J = 6.5 Hz, 2 H), 3.02 (s, 2 H), 2.81 (s, 3 H), 2.02 (t, J = 6.5, 2 H), 1.47(t, J = 7.1 Hz, 3 H); MS (ESI) m/z 350 [M + H]+; Anal. Calcd. for C17H19NO5S; C, 58.44; H, 5.48; N, 4.01; Found: C, 58.34; H, 5.46; N, 3.86. d) Ethyl 7,7-Ethylenedioxy-4-trifluoromethylsulfonyloxy- 2-methyl-5,6,7,8- tetrahydro-[l]benzothieno[2,3-b]pyridine-3-carboxylate
To a solution of compound of Example 3(c) (5.0 g, 14.3 mmol) in pyridine (50 mL) was added dropwise triflic anhydride (4.0 g, 14.2 mmol). The reaction mixture was then stirred at 0 °C for 4 h until complete. The reaction mixture was washed with aqueous copper sulfate solution (3x) followed by water (2x), and brine (2x). The organic layer evaporated, dried over anhydrous sodium sulfate and concentrated in vacuo. Purification by flash chromatography (silica gel, 1:1 hexane: ethyl acetate) yielded the title compound as a light yellow solid (3.7 g, 54%). mp 133-134 °C; lU NMR (400 MHz, CDC13) δ 4.43 (q, 7= 7.2 Hz, 2 H), 4.06 (s, 4 H), 3.16 (t, J= 6.5 Hz, 2 H), 3.10 (s, 2 H), 2.77 (s, 3 H), 2.03 (t, J = 6.8 Hz, 2 H), 1.41 (t, J = 7.1 Hz, 3 H); MS (ESI) m/z 482 [M + H]+; Anal. Calcd. for C18H18F3NO7S2; C, 44.90; H, 3.77; N, 2.91; Found: C, 45.03; H, 3.62; N, 2.89.
e) 8,8-Ethylenedioxy-2,3,7,8,9,10-hexahydro-4-methyl-lH-[l]benzothieno[2,3- b]pyrazolo[3,4-d]pyridin-3-one
To a solution of compound of Example 3(d) (2.4 g, 5.0 mmol) in methanol (40 mL) at room temperature was added hydrazine monohydrate (4.1 g, 82.3 mmol). The reaction mixture was heated at reflux for 3 h. The mixture was cooled then partitioned between pH 7 aqueous buffer and ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered, concentrated in vacuo and recystallized from methanol/ethyl acetate to yield the title compound as a light yellow solid (0.99 g, 60%). JH NMR (400 MHz, d4-MeOH) δ 4.05 (s, 4 H), 3.15 (t, J = 6.5 Hz, 2 H), 3.04 (s, 2 H), 2.82 (s, 3 H), 2.06 (t, J = 6.5 Hz, 2 H); MS (ESI) m/z 318 [M + H]+; Anal. Calcd. for C15H15N3θ3S.0.25 H2O: C, 55.97; H, 4.85; N, 13.05; Found: C, 55.85; H, 4.75; N, 13.30.
Example 4
Preparation of 1 ■4-Dimethyl-8.8-ethylenedioxy-2.3.7.8.9.10-hexahvdro- 1 H- fllbenzothienol2.3-blpyrazolor3.4-dlpyridin-3-one
Figure imgf000029_0001
l,4-Dimethyl-8,8-ethylenedioxy-2,3,7,8,9,10-hexahydro-lH-[l]benzothieno[2,3- b]pyrazolo[3,4-d]pyridin-3-one
A solution of compound of Example 3(d) (0.4 g, 0.83 mmol) in methanol (6.7 mL) at room temperature was treated with methylhydrazine (0.16 g, 3.45 mmol) and the mixture is heated at reflux for 2 h. The mixture was cooled and the precipitate, containing 150 mg of the 2,4-dimethyl regioisomer, filtered. The filtrate was evaporatewd and purified by flash chromatography (silica gel, elution with
80:20:5 ethyl acetate:methanol:acetic acid) to provide the title compound as a yellow solid (22 mg). ]H NMR (400 MHz, CDC13) δ 4.03 (s, 4 H), 3.73 (s, 3 H), 3.76 (t, J = 6.0 Hz, 2 H), 3.00 (s, 2 H), 2.80 (s, 3 H), 2.03 (t, J = 6.0 Hz, 2 H); MS (ESI) m/z 332 (M+H)+.
Example 5
Preparation of 8-rgrt-Butoxycarbonyl-2.3.7.8.9.10-hexahydro-4-methyl-lH- pyridor4'.3':4.51thienol2.3-blpyrazolor3.4-d1pyridin-3-one
Figure imgf000029_0002
a) N- r/-Butoxycarbonyl-4-( 1 -cyano- 1 -ethoxycarbonyl)methylenepiperidine To a mixture of N-tert-butoxycarbonyl-4-piperidone (25 g, 0.125 mol) and ethyl cyanoacetate (18 g, 0.160 mol) in toluene (400 mL) was added dropwise diethylamine (18.25 g, 0.25 mol) at room temperature. The reaction mixture was heated at reflux overnight, using a Dean Stark apparatus. The mixture was cooled and partitioned with ethyl acetate and saturated aqueous sodium bicarbonate (3x). The organic extracts were dried over sodium sulfate, filtered, concentrated in vacuo to yield 38 g of crude material. Purification by silica gel chromatography (70:30 hexanes : ethyl acetate) afforded the title compound as a white solid (22.2 g, 60%). !H NMR (300 MHz, CDC13) δ 4.31 (q, 7 = 7.1 Hz, 2 H), 3.63 (t, 7 = 5.5 Hz, 2 H), 3.56 (t, 7 = 5.5 Hz, 2 H), 3.12 (t, 7 = 5.5 Hz, 2 H), 2.78 (t, 7 = 5.5 Hz, 2 H), 2.83 (s, 3 H), 1.48 (s, 9 H), 1.35 (t, 7 = 7.1 Hz, 3 H); MS (ESI) m/z 295 [M + H]+.
b) Ethyl 2-Amino-8-terf-butoxycarbonyl-4,5,6,7- tetrahydropyrido[4,,3':4,5]thiophene-3-carboxylate To a suspension of compound of Example 5(a) (17 g, 58 mmol) and sulfur
(2.08 g, 65 mmol) in ethanol (160 mL) at 0 °C, was added dropwise a solution of diethylamine (4.75 g, 65 mmol) in ethanol (160 mL) and the mixture was stirred at 0 °C for 1 h, then at room temperature for 15 h. The resulting solid precipitate was filtered and the filtrate was diluted with water to afford an additional amount of precipitate. Overall, 15.6 g of title compound was obtained (82.5%): mp 153-154 °C; *H NMR (400 MHz, CDC13) δ 4.35 (s, 2 H), 4.27 (q, 7 = 7.2 Hz, 2 H), 3.62 (t, 7 = 5.8 Hz, 2 H), 2.80 (t, 7 = 5.8 Hz, 2 H), 1.48 (s, 9 H), 1.34 (t, 7 = 7.2 Hz, 3 H).
c) Ethyl 7-tert-Butoxycarbony l-4-hydroxy-2-methy 1-5 ,6,7,8- tetrahydropyrido[4',3':4,5]thieno[2,3-b]pyridine-2-carboxylate
A solution of compound of Example 5(b) (14.0 g, 42.9 mmol) in toluene (300 mL) at room temperature was treated with ethyl 3-ethoxycrotonate (13.6 g, 85.8 mmol) and camphorsulfonic acid (1.0 g, 4.3 mmol) and the resulting mixture was heated at reflux for 3.5 h using a Dean Stark trap. After cooling, the reaction mixture was treated with a solution of sodium ethoxide (55 mmol) in ethanol (60 mL). Once the addition was complete the reaction mixture was heated at reflux for 3 h. The mixture was cooled and neutralized with acetic acid to pH 6. It was then extracted with ethyl acetate and the resulting solution was dried over sodium sulfate, filtered, concentrated in vacuo to yield 14.5 g of an oily material. Purification by silica gel chromatography (95:5 dichloromethane : ethyl acetate) afforded the title compound as a white solid (11.5 g, 77%); *H NMR (300 MHz, CDC13) δ 12.8 (s, 1 H), 4.65 (s, 2 H), 4.49 (q, 7 = 7.1 Hz, 2 H), 3.75 (t, 7 = 5.6 Hz, 2 H), 3.13 (t, 7 = 5.6 Hz, 2 H), 2.83 (s, 3 H), 1.50 (s, 9 H), 1.48 (t, 7 = 7.1 Hz, 3 H).
d) Ethyl 7-^rf-Butoxycarbonyl-2-methyl-4-trifluoromethylsulfonyloxy-5, 6,7,8- tetrahydropyrido[4',3':4,5]thieno[2,3-b]pyridine-2-carboxylate
To a solution of compound of Example 5(c) (3.48 g, 10 mmol) in pyridine (25 mL) was added dropwise triflic anhydride (6.0 g, 2.5 mmol) under argon at -30 °C. The reaction mixture was then stirred at -30 °C for 30 min and at room temperature for 1 h. It was subsequently washed with aqueous copper sulfate solution (3x) followed by water (2x), and brine (2x). The organic layer was evaporated, dried over anhydrous sodium sulfate and concentrated in vacuo to afford the titie compound as a light yellow solid (4.38 g, 83.5%). lH NMR (400 MHz, CDC13) δ 4.73 (s, 2 H), 4.44 (q, 7 = 7.1 Hz, 2 H), 3.75 (t, 7 = 5.6 Hz, 2 H), 3.05 (t, 7 = 5.6 Hz, 2 H), 2.79 (s, 3 H), 1.51 (s, 9 H), 1.42 (t, 7 = 7.1 Hz, 3 H); MS (ESI) m/z 525 [M + H]+.
e) 8-tert-Butoxycarbonyl-2,3,7,8,9,10-hexahydro-4-methyl-lH- pyrido[4',3':4,5]thieno[2,3-b]pyrazolo[3,4-d]pyridin-3-one
To a solution of compound of Example 5(d) (4.0 g, 7.6 mmol) in methanol
(50 mL) at room temperature was added hydrazine monohydrate (3.0 g, 75 mmol). The reaction mixture was heated at reflux for 15 h. The mixture was concentrated to about 10 mL of solvent and it was then diluted with water. The resulting solid material was filtered to provide the title compound as a white powder (1.7 g, 62%). mp >300 °C Η NMR (400 MHz, d6-DMSO) δ 4.63 (s, 2 H), 3.71 (t, 7 = 5.6 Hz, 2 H), 3.33 (t, 7 = 5.6 Hz, 2 H), 2.69 (s, 3 H), 1.44 (s, 9 H); Anal. Calcd. for C17H2oN4O3S: C, 56.65; H, 5.59; N, 15.54; Found: C, 56.59; H, 5.63; N, 15.55; MS (ESI) m/z 361 [M + H]+.
Example 6
Preparation of 2.3.7.8.9.10-Hexahvdro-4-methyl-lH-pyridor4'.3':4.51thie.nor2.3- blpyrazoloβ ,4-dlpyridin-3-one
Figure imgf000032_0001
2,3,7,8,9,10-Hexahydro-4-methyl-lH-pyrido[4',3':4,5]thieno[2,3-b]pyrazolo[3,4- d]pyridin-3-one Trifluoroacetate Salt
To a suspension of compound of Example 5(e) (0.50 g, 1.39 mmol) in dichloromethane (15 mL) was added trifluoroacetic acid (3 mL) and the resulting clear solution was stirred at room temperature for 1.5 h. The mixture was concentrated under reducer pressure and then diluted with ethyl acetate to yield title compound as a yellowish solid material (0.494 g, 96%). mp 200-203 °C (dec); lH NMR (400 MHz, d6-DMSO) δ 4.48 (s, 2 H), 3.55 (t, 7 = 5.6 Hz, 2 H), 3.25 (t, 7 = 5.6 Hz, 2 H), 2.77 (s, 3 H); MS (ESI) m/z 261 [M + H]+.
EXAMPLE 7 An oral dosage form for administering Formula (HI) comounds is produced by screening, mixing, and filling into hard gelatin capsules the ingredients in the proportions shown in Table 1, below.
Table I Ingredients Amounts
8,8-Ethylenedioxy-2,3,7,8,9,10- 50 mg hexahydro-4-methyl- 1 H-
[l]benzothieno[2,3-b]pyrazolo[3,4- d]pyridin-3-one magnesium stearate 5 mg lactose 75 mg
EXAMPLE 8 The sucrose, calcium sulfate dihydrate and Formula (III) compound shown in Table II below, are mixed and granulated in the proportions shown with a 10% gelatin solution. The wet granules are screened, dried, mixed with the starch, talc and stearic acid, screened and compressed into a tablet.
Table II
Ingredients Amounts
8,8-Ethylenedioxy-2,3 ,7,8,9, 10- 100 mg hexahydro-4-methy 1- 1 H-
[ 1 ]benzothieno[2,3-b]pyrazolo[3,4- d]pyridin-3-one calcium sulfate dihydrate 150 mg sucrose 20 mg starch 10 mg talc 5 mg stearic acid 3 mg
EXAMPLE 9
8,8-Ethylenedioxy-2,3,7,8,9,10-hexahydro-4-methyl-lH-[l]benzothieno[2,3- b]pyrazolo[3,4-d]pyridin-3-one, 75 mg, is dispursed in 25 ml of normal saline to prepare an injectable preparation.
While the preferred embodiments of the invention are illustrated by the above, it is to be understood that the invention is not limited to the precise instructions herein disclosed and that the right to all modifications coming within the scope of the following claims is reserved.

Claims

What is claimed is:
1. A compound of Formula (I) :
Figure imgf000034_0001
wherein:
X is O or NR5, where R5 is hydrogen, or selected from: linear or branched Ci.galkyl, -(CH2)nC3_7cycloalkyl, linear or branched C2- lkenyl, linear and branched C2_6 lkynyl or -(CH2)nAr, all of which are optionally substituted with one or more substituents selected from the group consisting of: -OH, -OR6, -CONR6R7, -NR6R7, -COR6, -
CO2R6, -SO2NHR6, -NHCOR6 and halogen, where n is 0 to 6, and
R6 and R7 are: (i) hydrogen, or independently selected from: H, linear or branched C^galkyl, C3.
7cycloalkyl, linear or branched C2-6alkenyl, linear or branched C2- galkynyl and Ar, all of which are optionally substituted with one or more substituents selected from the group consisting of: -OH and halogen, or
(ii) when attached to the same nitrogen atom R6 and R7 can join together to form a ring selected from the group consisting of: piperidyl, morpholynyl, piperazinyl and pyrrolidyl;
R* is hydrogen, or selected from: linear or branched Cι_gal yl, -(CH2)nC3_7cycloalkyl, linear or branched C2-6 lkenyl, linear or branched C2_6 lkynyl and -(CH2)nAr, all of which are optionally substituted with one or more substituents selected from the group consisting of: -OH, -OR6, -CONR6R7, -NR R7, -COR6, -CO2R6, -SO2NHR6, - NHCOR6 and halogen, where n, R6 and R7 have the same meaning as above; and R2 and R3 are (i) hydrogen, or independently selected from: linear or branched Cj^alkyl, -(CH2)nC3_ 7cycloalkyl, linear or branched C2_6 lkenyl, linear or branched C2-6alkynyl and -(CH2)nAr, all of which are optionally substituted with one or more substituents selected from the group consisting of: -OH, -OR6, -CONR6R7, - NR6R7, -COR6, -CO2R6, -SO2NHR6, -NHCOR6 and halogen, where n, R6 and R7 have the same meaning as above, (ii) R2 and R3 are joined together to form a non aromatic saturated or unsaturated C3_i2cy loalkyl, optionally containing one or two heteroatoms, and optionally substituted with one or more substituents selected from the group consisting of: ethylenedioxy, linear or branched Cι_galkyl, -
(CH2)nC3_7cycloalkyl, linear or branched C2-6 lkenyl, linear or branched C2-6alkynyl, -(CH2)nAr, -OH, -OR6, -CONR6R7, -COR6, -CO2R6, - SO NHR6, -NHCOR6 and halogen, where n, R6 and R7 have the same meaning as above, or (iii) R2 and R3 are joined together to form an aromatic ring selected from the group consisting of: phenyl, naphthyl, furyl, pyrrolyl, thienyl, isothiazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrazinyl, pyrimidyl, pyridazinyl, carbazolyl, indolyl, quinolyl and purinyl, all of which are optionally substituted with one or more substituents selected from the group consisting of: halogen, -OH, linear or branched C]_6alkyl, -(CH2)nC3-7cycloalkyl, linear or branched C2-6alkenyl, -(CH2)nPh, -O-C^alkyl, -CONR6R7, - NR6R7, -COR6, -CO2R6, -SO2NHR6, -NHCOR6 and halogen, where n, R6 and R7 have the same meaning as above; or a pharmaceutically acceptable salt, hydrate or solvate thereof; except 2,3,7,8,9,10-Hexahydro-4-methyl-lH-[l]benzothieno[2,3-b]pyrazolo[3,4- d]pyridin-3-one and 8, 8-Ethylenedioxy-2, 3,7,8,9, 10-hexahydro-4-methyl-lH- [l]benzothieno[2,3-b]pyrazolo[3,4-d]pyridin-3-one; but including pharmaceutically acceptable salts, hydrates and solvates of 2,3,7,8,9, 10-Hexahydro-4-methyl-lH- [l]benzothieno[2,3-b]pyrazolo[3,4-d]pyridin-3-one and 8,8-Ethylenedioxy-
2,3,7,8,9,10-hexahydro-4-methyl-lH-[l]benzothieno[2,3-b]pyrazolo[3,4-d]pyridin- 3-one.
2. A compound of claim 1 wherein: X is O or NR5, where R5 is hydrogen, or selected from: linear or branched Cj^alkyl, -(CH2)nC3_7cycloalkyl, linear or branched C2-6alkenyl, linear and branched C2_6alkynyl or -(CH2)nAr, where n is 0 to 6; Rl is hydrogen, or selected from: linear or branched C^alkyl, -(CH2)nC3_7cycloalkyl, linear or branched C2-6alkenyl, linear or branched C2_6alkynyl and -(CH2)nAr, where n has the same meaning as above; and R2 and R3 are (i) hydrogen, or independently selected from: linear or branched Cι_6alkyl, -(CH2)nC3_ 7cycloalkyl, linear or branched C2-6aUcenyl, linear or branched C2-6 lkynyl and -(CH2)nAr, where n has the same meaning as above, (ii) R2 and R3 are joined together to form a non aromatic saturated or unsaturated C3_ ^cycloalkyl, optionally containing one nitrogen atom, and optionally substituted with one substituent selected from the group consisting of: ethylenedioxy, linear or branched Cj^alkyl, -(CH2)nC3_ 7cycloalkyl, linear or branched C2-6 lkenyl, linear or branched C2_6alkynyl, -(CH2)nAr, -OH, -OR6, -CONR6R7, -COR6, -CO2R6, -SO2NHR6, -
NHCOR6 and halogen, where n has the same meaning as above, or (iii) R2 and R3 are joined together to form an aromatic ring selected from the group consisting of: phenyl, naphthyl, furyl, pyrrolyl, thienyl, isothiazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrazinyl, pyrimidyl, pyridazinyl, carbazolyl, indolyl, quinolyl and purinyl, all of which are optionally substituted with one or more substituents selected from the group consisting of: halogen, -OH, linear or branched Cj.galkyl, -(CH2)nC3_7cycloalkyl, linear or branched C2-6 lkenyl, -(CH2)nPh, -O-Cι_6alkyl and halogen, where n has the same meaning as above; or a pharmaceutically acceptable salt, hydrate or solvate thereof; except 2,3,7,8,9,10-Hexahydro-4-methyl-lH-[l]benzothieno[2,3-b]pyrazolo[3,4- d]pyridin-3-one and 8,8-Ethylenedioxy-2,3,7,8,9,10-hexahydro-4-methyl-lH- [l]benzothieno[2,3-b]pyrazolo[3,4-d]pyridin-3-one; but including pharmaceutically acceptable salts, hydrates and solvates of 2,3,7,8,9,10-Hexahydro-4-methyl-lH- [l]benzothieno[2,3-b]pyrazolo[3,4-d]pyridin-3-one and 8,8-Ethylenedioxy- 2,3,7,8,9, 10-hexahydro-4-methyl-lH-[l]benzothieno[2,3-b]pyrazolo[3,4-d]pyridin- 3-one.
3. A compound of claim 1 in which:
X is NR5, where R5 is hydrogen, or selected from: linear or branched Cι_6alkyl, C3_7cycloalkyl and phenyl;
R1 is hydrogen, or selected from: linear or branched Cι_6alkyl, C3_7cycloalkyl and phenyl; and
R2 and R3 are
(i) hydrogen, or independently selected from: linear or branched Cj.galkyl, C3_7cycloalkyl and phenyl, (ii) R2 and R3 are joined together to form a non aromatic saturated or unsaturated C5_7cycloalkyl, optionally containing one nitrogen heteroatom, and optionally substituted with one or more substituents selected from the group consisting of: ethylenedioxy, linear or branched Cj^alkyl, C3_7cycloalkyl, phenyl,- OH, -OR6, -CONR6R7, -COR6, -CO2R6, -SO2NHR6, - NHCOR6 and halogen, or (iii) R2 and R3 are joined together to form a phenyl ring, optionally substituted with one or more substituents selected from the group consisting of: halogen, -OH, linear or branched Cj.galkyl, C3_7cycloalkyl and phenyl; except 2,3,7,8,9,10-Hexahydro-4-methyl-lH-[l]benzothieno[2,3-b]pyrazolo[3,4- d]pyridin-3-one and 8,8-Ethylenedioxy-2,3,7,8,9, 10-hexahydro-4-methyl- 1H- [l]benzothieno[2,3-b]pyrazolo[3,4-d]pyridin-3-one.
4. A compound of claim 1 selected from: 2,3-Dihydro-4-methyl-lH-[l]benzothieno[2,3-b]pyrazolo[3,4-d]pyridin-3-one and pharmaceutically acceptable salts, hydrates and solvates thereof; A pharmaceutically acceptable salt, hydrate or solvate of 2,3,7,8,9,10-
Hexahydro-4-methyl-lH-[l]benzothieno[2,3-b]pyrazolo[3,4-d]pyridin-3-one; l,4-Dimethyl-8,8-ethylenedioxy-2,3,7,8,9,10-hexahydro-lH- [l]benzothieno[2,3-b]pyrazolo[3,4-d]pyridin-3-one and pharmaceutically acceptable salts, hydrates and solvates thereof; A pharmaceutically acceptable salt, hydrate or solvate of 8,8-Ethylenedioxy-
2,3 ,7,8,9, 10-hexahydro-4-methyl- 1 H-[ 1 ]benzothieno[2,3-b]pyrazolo[3,4-d]pyridin- 3-one;
8-terr-Butoxycarbony 1-2,3 ,7,8,9, 10-hexahydro-4-methyl- 1 H- pyrido[4',3':4,5]thieno[2,3-b]pyrazolo[3,4-d]pyridin-3-one and pharmaceutically acceptable salts, hydrates and solvates thereof; and
2,3,7,8,9,10-Hexahydro-4-methyl-lH-pyrido[4',3':4,5]thieno[2,3- b]pyrazolo[3,4-d]pyridin-3-one and pharmaceutically acceptable salts, hydrates and solvates thereof.
5. A method of enhancing erythropoiesis in a subject which comprises administering to a subject in need of such therapy an effective amount of a compound of Formula (IH):
Figure imgf000039_0001
wherein:
X is O or NR5, where R5 is hydrogen, or selected from: linear or branched Cj.galkyl, -(CH2)nC3-7cycloalkyl, linear or branched C2-6 lkenyl, linear and branched C2-6 lkynyl or -(CH2)nAr, all of which are optionally substituted with one or more substituents selected from the group consisting of: -OH, -OR6, -CONR6R7, -NR6R7, -COR6, - CO2R6, -SO NHR6, -NHCOR6 and halogen, where n is 0 to 6, and R6 and R7 are: (i) hydrogen, or independently selected from: H, linear or branched C galkyl, C3. 7cycloalkyl, linear or branched C2-6 lkenyl, linear or branched C2- galkynyl and Ar, all of which are optionally substituted with one or more substituents selected from the group consisting of: -OH and halogen, or
(ii) when attached to the same nitrogen atom R6 and R7 can join together to form a ring selected from the group consisting of: piperidyl, morpholynyl, piperazinyl and pyrrolidyl; R * is hydrogen, or selected from: linear or branched C \ _6alkyl, -(CH2)nC3_7cycloalkyl, linear or branched C2-6alkenyl, linear or branched C2_6alkynyl and -(CH2)nAr, all of which are optionally substituted with one or more substituents selected from the group consisting of: -OH, -OR6, -CONR6R7, -NR6R7, -COR6, -CO R6, -SO2NHR6, - NHCOR6 and halogen, where n, R6 and R7 have the same meaning as above; and R2 and R3 are (i) hydrogen, or independently selected from: H, linear or branched Cj^alkyl, -(CH2)nC3_ 7cycloalkyl, linear or branched C2-6al enyl, linear or branched C2-6alkynyl and -(CH2)nAr, all of which are optionally substituted with one or more substituents selected from the group consisting of: -OH, -OR6, -CONR R7, - NR6R7, -COR6, -CO2R6, -SO2NHR6, -NHCOR6 and halogen, where n, R6 and R7 have the same meaning as above, (ii) R2 and R3 are joined together to form a non aromatic saturated or unsaturated C3. ^cycloalkyl, optionally containing one or two heteroatoms, and optionally substituted with one or more substituents selected from the group consisting of: ethylenedioxy, linear or branched C^galkyl, -
(CH2)nC3_7cycloalkyl, linear or branched C2-6alkenyl, linear or branched C2-6alkynyl, -(CH2)nAr, -OH, -OR6, -CONR R7, -COR6, -CO2R6, - SO2NHR6, -NHCOR6 and halogen, where n, R6 and R7 have the same meaning as above, or (iii) R2 and R3 are joined together to form an aromatic ring selected from the group consisting of: phenyl, naphthyl, furyl, pyrrolyl, thienyl, isothiazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrazinyl, pyrimidyl, pyridazinyl, carbazolyl, indolyl, quinolyl and purinyl, all of which are optionally substituted with one or more substituents selected from the group consisting of: halogen, -OH, linear or branched C^galkyl, -(CH2)nC3-7cycloalkyl, linear or branched C2-6alkenyl, -(CH2)nPh, -O-Cι_$alkyl, -CONR6R7, - NR6R7, -COR6, -CO2R6, -SO2NHR6, -NHCOR6 and halogen, where n, R6 and R7 have the same meaning as above; or a pharmaceutically acceptable salt, hydrate or solvate thereof.
6. The method of claim 5 wherein: X is O or NR5, where R5 is hydrogen, or selected from: linear or branched Cι_($alkyl, -(CH2)nC3-7cycloalkyl, linear or branched C2-6alkenyl, linear and branched C2-6alkynyl or -(CH2)nAr, where n is 0 to 6; Rl is hydrogen, or selected from: linear or branched Ci^alkyl, -(CH2)nC3_7cycloalkyl, linear or branched C2-6aMcenyl» linear or branched C2-6alkynyl and -(CH2)nAr, where n has the same meaning as above; and
R2 and R3 are
(i) hydrogen, or independently selected from: linear or branched Cj.galkyl, -(CH2)nC3_ 7cycloalkyl, linear or branched C2-6alkenyl, linear or branched C2_6 lkynyl and -(CH2)nAr, where n has the same meaning as above, (ii) R2 and R3 are joined together to form a non aromatic saturated or unsaturated C3. ^cycloalkyl, optionally containing one nitrogen atom, and optionally substituted with one substituent selected from the group consisting of: ethylenedioxy, linear or branched Cj^alkyl, -(CH2)nC3_
7cycloalkyl, linear or branched C2-6 lkenyl, linear or branched C2-6alkynyl, -(CH2)nAr, -OH, -OR6, -CONR R7, -COR6, -CO2R6, -SO2NHR6, - NHCOR6 and halogen, where n has the same meaning as above, or (iii) R2 and R3 are joined together to form an aromatic ring selected from the group consisting of: phenyl, naphthyl, furyl, pyrrolyl, thienyl, isothiazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrazinyl, pyrimidyl, pyridazinyl, carbazolyl, indolyl, quinolyl and purinyl, all of which are optionally substituted with one or more substituents selected from the group consisting of: halogen, -OH, linear or branched Cj.galkyl, -(CH2)nC3_7cycloalkyl, linear or branched C2-6alkenyl, -(CH2)nPh, -O-Ci.galkyl and halogen, where n has the same meaning as above; or a pharmaceutically acceptable salt, hydrate or solvate thereof.
7. The method of claim 5 in which: X is NR5, where R5 is hydrogen, or selected from: linear or branched Cj.galkyl, C3_7cycloalkyl and phenyl; Rl is hydrogen, or selected from: linear or branched Ci.galkyl, C3_7cycloalkyl and phenyl; and
R2 and R3 are
(i) hydrogen, or independently selected from: linear or branched Cj.galkyl, C3_7cycloalkyl and phenyl,
(ii) R2 and R3 are joined together to form a non aromatic saturated or unsaturated C5_7cycloalkyl, optionally containing one nitrogen heteroatom, and optionally substituted with one or more substituents selected from the group consisting of: ethylenedioxy, linear or branched Cj.galkyl, C3_7cycloalkyl, phenyl,- OH, -OR6, -CONR R7, -COR6, -CO2R6, -SO2NHR6, - NHCOR6 and halogen, or
(iii) R2 and R3 are joined together to form a phenyl ring, optionally substituted with one or more substituents selected from the group consisting of: halogen, -OH, linear or branched C^alkyl, C3_7cycloalkyl and phenyl; except 2,3,7,8,9,10-Hexahydro-4-methyl-lH-[l]benzothieno[2,3-b]pyrazolo[3,4- d]pyridin-3-one and 8,8-Ethylenedioxy-2,3,7,8,9, 10-hexahydro-4-methyl-lH-
[ 1 ]benzothieno[2,3-b]pyrazolo[3,4-d]pyridin-3-one.
8. The method of claim 5 wherein the compound is selected from: 2,3,7,8,9, 10-Hexahydro-4-methyl- lH-[ 1 ]benzothieno[2,3-b]pyrazolo[3,4- d]pyridin-3-one and pharmaceutically acceptable salts, hydrates and solvates thereof; 2,3-Dihydro-4-methyl- lH-[ 1 ]benzothieno[2,3-b]pyrazolo[3,4-d]pyridin-3- one and pharmaceutically acceptable salts, hydrates and solvates thereof;
8,8-Ethylenedioxy-2,3,7,8,9,10-hexahydro-4-methyl-lH-[l]benzothieno[2,3- b]pyrazolo[3,4-d]pyridin-3-one and pharmaceutically acceptable salts, hydrates and solvates thereof; l,4-Dimethyl-8,8-ethylenedioxy-2,3,7,8,9,10-hexahydro-lH- [l]benzothieno[2,3-b]pyrazolo[3,4-d]pyridin-3-one and pharmaceutically acceptable salts, hydrates and solvates thereof;
8- rt-Butoxycarbonyl-2,3,7,8,9, 10-hexahydro-4-methyl- 1 H- pyrido[4',3':4,5]thieno[2,3-b]pyrazolo[3,4-d]pyridin-3-one and pharmaceutically acceptable salts, hydrates and solvates thereof; and
2,3,7,8,9,10-Hexahydro-4-methyl-lH-pyrido[4',3':4,5]thieno[2,3- b]pyrazolo[3,4-d]pyridin-3-one and pharmaceutically acceptable salts, hydrates and solvates thereof.
9. Use of a compound according to any one of claims 1 to 4 in the manufacture of a medicament for use in enhancing erythropoiesis.
10. A pharmaceutical composition comprising a suitable pharmaceutical carrier and a compound of Formula (III) as described in claim 5.
11. A composition of claim 10 wherein the compound is 2,3,7,8,9,10-Hexahydro-4-methyl-lH-[l]benzothieno[2,3-b]pyrazolo[3,4- d]pyridin-3-one and pharmaceutically acceptable salts, hydrates and solvates thereof; 2,3-Dihydro-4-methyl- 1 H-[ 1 ]benzothieno[2,3-b]pyrazolo[3,4-d]pyridin-3- one and pharmaceutically acceptable salts, hydrates and solvates thereof;
8,8-Ethylenedioxy-2,3,7,8,9,10-hexahydro-4-methyl-lH-[l]benzothieno[2,3- b]pyrazolo[3,4-d]pyridin-3-one and pharmaceutically acceptable salts, hydrates and solvates thereof; l,4-Dimethyl-8,8-ethylenedioxy-2,3,7,8,9,10-hexahydro-lH- [l]benzothieno[2,3-b]pyrazolo[3,4-d]pyridin-3-one and pharmaceutically acceptable salts, hydrates and solvates thereof;
8-tørf-Butoxycarbonyl-2,3,7,8,9, 10-hexahydro-4-methyl- 1H- pyrido[4',3':4,5]thieno[2,3-b]pyrazolo[3,4-d]pyridin-3-one and pharmaceutically acceptable salts, hydrates and solvates thereof; and
2,3 ,7,8,9, 10-Hexahydro-4-methyl- 1 H-pyrido[4',3':4,5]thieno[2,3- b]pyrazolo[3,4-d]pyridin-3-one and pharmaceutically acceptable salts, hydrates and solvates thereof.
12. A process for the preparation of a compound of Formula (I)
Figure imgf000044_0001
in which X is NR5 and NR5, R*, R2 and R3 are as described in claim 1 above, including the exceptions, and pharmaceutically acceptable salts, hydrates and solvates thereof comprises reacting a compound of the Formula
Figure imgf000044_0002
in which Rl, R2 and R3 are as described above with a hydrazine derivative of the formula
H
/
N^
R 2 where R5 is as described in Formula (I) above; in a solvent, such as methanol, at reflux and thereafter optionally forming a pharmaceutically acceptable salt, hydrate or solvate thereof.
13. A process for preparing a pharmaceutical composition containing a pharmaceutically acceptable carrier or diluent and an effective amount of a compound of the Formula (III) as described in claim 5, which process comprises bringing the compound of the Formula (III) into association with the pharmaceutically acceptable carrier or diluent.
14. A compound of the Formula ( V) :
Figure imgf000045_0001
in which Rl is as described in Formula (I) in claim 1; and R2 and R3 are joined together to form a non aromatic saturated or unsaturated C3. ^cycloalkyl, optionally containing one or two heteroatoms, and optionally substituted with one or more substituents selected from the group consisting of: ethylenedioxy, linear or branched Cj^alkyl, -(CH2)nC3_7cycloalkyl, linear or branched C2-6alkenyl, linear or branched C2-6al ynyl, -(CH2)nAr, -OH, -OR6, - CONR6R7, -COR6, -CO2R6, -SO2NHR6, -NHCOR6 and halogen, where n, R6 and R7 have the same meaning as in Formula (I) in claim 1.
PCT/US1996/020418 1995-12-29 1996-12-20 THIENO(2,3-b)PYRAZOLO(3,4-d)PYRIDIN-3-ONES TO ENHANCE ERYTHROPOIESIS WO1997024120A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
BR9612302A BR9612302A (en) 1995-12-29 1996-12-20 Tieno [2,3-b] -pyrazolo [3,4-d] pyridin-3-ones to improve erythropoiesis
JP09524480A JP2000507206A (en) 1995-12-29 1996-12-20 Thieno [2,3-b] pyrazolo [3,4-d] pyridin-3-ones that enhance erythropoiesis
EP96945632A EP0869790A4 (en) 1995-12-29 1996-12-20 THIENO(2,3-b)PYRAZOLO(3,4-d)PYRIDIN-3-ONES TO ENHANCE ERYTHROPOIESIS
AU16867/97A AU1686797A (en) 1995-12-29 1996-12-20 Thieno(2,3-b)pyrazolo(3,4-d)pyridin-3-ones to enhance erythropoiesis
IL12503596A IL125035A0 (en) 1995-12-29 1996-12-20 Thieno (2,3-b) pyrazolo (3,4-d) pyridin-3-ones to enhance erythropoiesis
KR1019980704948A KR19990076822A (en) 1995-12-29 1996-12-20 (2,3-B) pyrazolo [3,4-d] pyridin-3-one for increasing erythropoiesis
NO983007A NO983007L (en) 1995-12-29 1998-06-26 Tieno (2,3-b) pyrazolo (3,4.d) pyridin-3-ones to increase erythropoiesis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US937195P 1995-12-29 1995-12-29
US60/009,371 1995-12-29
US1207096P 1996-02-22 1996-02-22
US60/012,070 1996-02-22

Publications (1)

Publication Number Publication Date
WO1997024120A1 true WO1997024120A1 (en) 1997-07-10

Family

ID=26679395

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/020418 WO1997024120A1 (en) 1995-12-29 1996-12-20 THIENO(2,3-b)PYRAZOLO(3,4-d)PYRIDIN-3-ONES TO ENHANCE ERYTHROPOIESIS

Country Status (16)

Country Link
US (1) US6107304A (en)
EP (1) EP0869790A4 (en)
JP (1) JP2000507206A (en)
KR (1) KR19990076822A (en)
CN (1) CN1211920A (en)
AU (1) AU1686797A (en)
BR (1) BR9612302A (en)
CA (1) CA2241723A1 (en)
CZ (1) CZ206498A3 (en)
HU (1) HUP9902086A3 (en)
IL (1) IL125035A0 (en)
MX (1) MX9805321A (en)
NO (1) NO983007L (en)
PL (1) PL327510A1 (en)
TR (1) TR199801251T2 (en)
WO (1) WO1997024120A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000046207A1 (en) * 1999-02-04 2000-08-10 Bayer Aktiengesellschaft Pyrazole alkylamides
WO2001000601A1 (en) * 1999-06-29 2001-01-04 Bayer Aktiengesellschaft Novel 4-(2-oxodihydrooxadiazinylphenyl)amides and the use thereof for treating anemia

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050084908A1 (en) * 2000-11-06 2005-04-21 Chugai Seiyaku Kabushiki Kaisha Methods for detecting binding of low-molecular-weight compound and its binding partner molecule
US6833374B2 (en) 2002-07-29 2004-12-21 Wyeth Dihydropyrazolo[3,4-d]thieno[2,3-B]pyridinone inhibitors of B7-1

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0727211A1 (en) * 1995-02-10 1996-08-21 Smithkline Beecham Corporation Use of src SH2 specific compounds to treat a bone resorption disease
EP0728482A2 (en) * 1995-02-10 1996-08-28 Smithkline Beecham Corporation Use of hcp specific compounds to enhance erythropoiesis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2435025C2 (en) * 1973-07-23 1985-01-17 Takeda Chemical Industries, Ltd., Osaka 4,7-Dihydro-4-oxo-thieno [2,3-b] pyridine-5-carboxylic acid and its derivatives and processes for their preparation
DE2447477A1 (en) * 1974-10-03 1976-04-15 Schering Ag Oxo-thieno-pyridine-carboxylic acid derivs. - prepd. by cyclizing 2-(2-thienylaminomethylene)malonic acid derivs.
EP0126970A3 (en) * 1983-04-27 1985-11-06 Beecham Group Plc Anxiolytic and anti-depressant thienopyridine derivatives
US4647566A (en) * 1984-07-09 1987-03-03 Ciba-Geigy Corporation Certain ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives in treating anxiety
US4740512A (en) * 1984-07-09 1988-04-26 Ciba-Geigy Corporation Treating anxiety with certain ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives
US4602014A (en) * 1984-07-09 1986-07-22 Ciba-Geigy Corporation Ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives as benzodiazepine receptor modulators
US4814450A (en) * 1984-07-09 1989-03-21 Ciba-Geigy Corporation Certain ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0727211A1 (en) * 1995-02-10 1996-08-21 Smithkline Beecham Corporation Use of src SH2 specific compounds to treat a bone resorption disease
EP0728482A2 (en) * 1995-02-10 1996-08-28 Smithkline Beecham Corporation Use of hcp specific compounds to enhance erythropoiesis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts Service (C A S); 1 January 1978 (1978-01-01), GILIS P M, HAEMERS A, BOLLAERT W: "SYNTHESIS AND ANTIBACTERIAL EVALUATION OF 4,7-DIHYDRO-4-OXOTHIENOÄ2,3-BÜPYRIDINE-5-CARBOXYLIC ACIDS", XP002943883, Database accession no. 89-129437Q *
MISBAHUL AIN KHAN, ET AL.: "1H-PYRAZOLO¬3,4-D¾THIENO¬2,3-B¾PYRIDINE AND ITS DERIVATIVES THE SYNTHESIS OF THE PARENT RING SYSTEM AND SOME OF THE DERIVATIVESOF 1H-PYRAZOLO¬3,4-D¾THIENO¬2,3-B¾PYRIDINE ARE DISCRIBED", JOURNAL OF HETEROCYCLIC CHEMISTRY, WILEY-BLACKWELL PUBLISHING, INC., US, vol. 20, 1 March 1983 (1983-03-01), US, pages 475/476, XP000983406, ISSN: 0022-152X *
See also references of EP0869790A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000046207A1 (en) * 1999-02-04 2000-08-10 Bayer Aktiengesellschaft Pyrazole alkylamides
WO2001000601A1 (en) * 1999-06-29 2001-01-04 Bayer Aktiengesellschaft Novel 4-(2-oxodihydrooxadiazinylphenyl)amides and the use thereof for treating anemia

Also Published As

Publication number Publication date
BR9612302A (en) 1999-07-13
MX9805321A (en) 1998-10-31
AU1686797A (en) 1997-07-28
HUP9902086A2 (en) 1999-11-29
IL125035A0 (en) 1999-01-26
HUP9902086A3 (en) 2001-09-28
NO983007L (en) 1998-08-26
CN1211920A (en) 1999-03-24
KR19990076822A (en) 1999-10-15
EP0869790A4 (en) 2001-04-11
EP0869790A1 (en) 1998-10-14
JP2000507206A (en) 2000-06-13
NO983007D0 (en) 1998-06-26
TR199801251T2 (en) 1998-10-21
US6107304A (en) 2000-08-22
PL327510A1 (en) 1998-12-21
CZ206498A3 (en) 1998-11-11
CA2241723A1 (en) 1997-07-10

Similar Documents

Publication Publication Date Title
US5366972A (en) 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection
JP4494205B2 (en) Calcium receptor modulating compound and use thereof
AU630251B2 (en) Dipyridodiazepines
WO1996011929A1 (en) Biheteroaryl-carbonyl and carboxamide derivatives with 5ht 2c/2b antagonists activity
WO2003057696A1 (en) Deazapurines and uses thereof
CZ224897A3 (en) Tricyclic diazepine derivatives, process of their preparation and pharmaceutical composition containing thereof
EP0003016B1 (en) Pyrazino-benzoxazepine and -benzthiazepine derivatives, processes for their production and pharmaceutical compositions containing them
US4239887A (en) Pyridothienotriazines
EP0869790A1 (en) THIENO(2,3-b)PYRAZOLO(3,4-d)PYRIDIN-3-ONES TO ENHANCE ERYTHROPOIESIS
US6653476B2 (en) Thienopyridine derivatives, their production and use
CN114616234B (en) Phosphorus imidazoquinoline amine derivative, pharmaceutical composition and application thereof
IE67509B1 (en) Pyridobenzoindole compositions their preparation and compositions containing them
JP2005239611A (en) Pyrazolopyrimidine derivative and its application
IE842663L (en) FURO £3,4-c| PYRIDINES
US3887570A (en) Derivatives of pyrazolo(3,4-b)thieno(2,3-d)pyridine-2-carboxylic acids
CN114276351B (en) Nitrogen-containing heterocyclic derivative, preparation method and medical application thereof
US4474786A (en) Tricyclic lactams and derivatives useful in increasing cardiac contractility
EP0653426A1 (en) Indole derivatives, salts thereof and heart affection therapeutic agent comprising the same
NZ197248A (en) Imidazole derivatives
US4639457A (en) Benzocycloheptapyridone compounds for treating congestive heart failure
JPH07620B2 (en) Condensed imidazopyridine derivative
WO2004063336A2 (en) Uses of deazapurines for the treatment of reperfusion injuries, osteoporosis and/or bone metastasis
KR20090040304A (en) Camptothecin derivatives with antitumor activity

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96180144.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU BB BG BR CA CN CZ EE GE HU IL IS JP KG KP KR LK LR LT LV MD MG MK MN MX NO NZ PL RO SG SI SK TR TT UA US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 330785

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2241723

Country of ref document: CA

Ref document number: 2241723

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1019980704948

Country of ref document: KR

Ref document number: PV1998-2064

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/1998/005321

Country of ref document: MX

Ref document number: 1998/01251

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 1996945632

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996945632

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1998-2064

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019980704948

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV1998-2064

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1019980704948

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1996945632

Country of ref document: EP